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CHAPTER I 
 
THE HIGH-AFFINITY CHOLINE TRANSPORTER – A CRITICAL PROTEIN  
FOR SUSTAINING CHOLINERGIC SIGNALING 
 
CHT Function and Regulation 
 
Cholinergic Neuroanatomy 
The presynaptic high-affinity choline transporter (CHT) derives its physiological 
importance from its support of the synthesis of the neurotransmitter acetylcholine (ACh). 
ACh plays an important role in both central and peripheral nervous systems, where it 
maintains vital biological functions such as motor function, attention, memory, reward, 
and autonomic regulation (Dani, 2001; Fink-Jensen et al., 2003; Kitabatake et al., 2003; 
Misgeld et al., 2002; Perry et al., 1999b; Sarter and Bruno, 1997; Wess, 2004; Winkler et 
al., 1995). Major cholinergic nuclei and their neuroanatomical connections include (Fig. 
1): septo-hippocampal projections, supporting learning and memory processes; basal 
forebrain – cortical projections, supporting attention and arousal; large aspinal 
cholinergic interneurons, which modulate striatal function and are increasingly implicated 
as modulators of movement, attention, and reward processes; medial habenula – 
interpeduncular nucleus projections; and mesopontine tegmental nuclei, including the 
pedunculopontine (PPT) and laterodorsal (LDT) tegmental nuclei, projecting to various 
brain structures, including the basal forebrain and the ventral tegmental area (VTA), the 
latter connections being strongly implicated in reward and addiction. In addition, 
brainstem and spinal cord cholinergic motor neurons support movement, while
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Figure 1. Cholinergic pathways in the brain.  The basal forebrain complex includes the 
diagonal band nuclei, nucleus basalis, substantia inominata, and magnocellular preoptic 
nucleus and provides cholinergic innervation to the cortex. The medial septum, habenula, 
and mesopontine tegmentum (LDT, PPT) originate major cholinergic projections to the 
hippocampus, IPN, and midbrain (VTA) respectively. Cholinergic interneurons are found 
in the striatum, nucleus accumbens, olfactory tubercle, and the islands of Calleja. BFC, 
basal forebrain complex; IPN, interpeduncular nucleus; LDT, laterodorsal tegmental 
nucleus; PPT, pedunculopontine tegmental nucleus; VTA, ventral tegmental area.  
Adapted from Piccioto et al. (2002).  
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cholinergic cells in the intermediolateral column of the spinal cord participate in 
autonomic nervous system regulation. 
 
The Cholinergic Synapse 
The turnover of ACh in cholinergic neurons involves a well-studied cycle of 
synthesis, release, hydrolysis, and reuptake (Fig. 2). The enzyme choline 
acetyltransferase (ChAT) synthesizes ACh in the axoplasm from the precursors choline 
and acetyl coenzymeA (acetyl-CoA). ChAT is not believed to be saturated with the 
substrate choline, as presynaptic levels of choline are significantly lower than ChAT Km. 
ACh is packaged into synaptic vesicles by the vesicular ACh transporter (VAChT), and 
released into the synaptic cleft upon depolarization of the neuron by an action potential. 
Once released in the synaptic cleft, ACh interacts with pre and post-synaptic nicotinic 
(nAChR) and muscarinic (mAChR) receptors and is inactivated enzymatically, through 
hydrolysis, into acetate and choline by the enzyme acetylcholinesterase (AChE). The 
choline released by hydrolysis is recycled at the presynaptic terminal via a distinct, 
carrier-mediated mechanism of high-affinity choline uptake (HACU). Low affinity 
choline uptake (LACU) transporters are found in all cell types, are not enriched in nerve 
terminals, and take up choline to be used in phosphatidylcholine synthesis in order to 
support cellular membrane maintenance and repair needs (Bussiere et al., 2001). 
Cholinergic neurons have an added requirement, elaborated in the presynaptic terminal, 
for choline, which they cannot synthesize de novo, but need as a substrate for ACh 
synthesis. This need is supported by the HACU mechanism. 
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Figure 2. The cholinergic synapse. The enzyme choline acetyltransferase (ChAT) 
synthesizes ACh in the axoplasm from the precursors choline and acetyl coenzymeA 
(acetyl-CoA). ACh is then packaged into synaptic vesicles by the vesicular ACh 
transporter (VAChT), and released into the synaptic cleft upon neuronal depolarization. 
In the synaptic cleft, ACh interacts with pre- and post-synaptic nicotinic (nAChR) and 
muscarinic (mAChR) receptors. Presynaptic mAChRs exert an autoinhibitory effect on 
ACh release, whereas presynaptic nAChR activation increases ACh release. Synaptic 
ACh is hydrolyzed into acetate and choline by the enzyme acetylcholine esterase 
(AChE). Choline is then transported into the presynaptic terminal by the HC-3 sensitive, 
high-affinity choline transporter (CHT), in the rate-limiting step of subsequent ACh 
synthesis.  
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High-Affinity Choline Uptake (HACU) and Cholinergic Neurotransmission 
Selective blockade or genetic ablation of the rate-limiting step in ACh synthesis - 
CHT-mediated HACU - reduces ACh synthesis and release in vitro (Fig. 3), and impairs 
cholinergic transmission at central and peripheral synapses in vivo (Ferguson et al., 2004; 
Guyenet et al., 1973; Macintosh et al., 1956; Maire and Wurtman, 1985). Breakdown of 
cholinergic signaling at the neuromuscular junction (NMJ) due to CHT dysfunction leads 
to lethal respiratory paralysis and demonstrates the essential physiological role of CHT 
(Ferguson et al., 2004; Schueler, 1955). 
 The HACU process was described as early as 1961 (Birks and McIntosh, 1961). 
Subsequent work showed it is present primarily in cholinergic nerve terminals (Kuhar 
and Murrin, 1978a; Kuhar et al., 1973), where it takes up choline specifically for the 
biosynthesis and replenishment of ACh pools (Blusztajn, 1998; Bussiere et al., 2001; 
Haga and Noda, 1973; Kuhar et al., 1973; Yamamura and Snyder, 1972). HACU displays 
affinity for choline in the lower micromolar range (KmHACU =1-5 µM, versus KmLACU=50 
µM) is a Na+- and Cl--dependent process (versus Na+/Cl—independent LACU), and is 
inhibited by the selective and competitive antagonist hemicholinium-3 (HC-3) (KiHACU = 
10-100 nM, versus KiLACU=50 µM) (Kuhar and Murrin, 1978a; Simon and Kuhar, 1976; 
Yamamura and Snyder, 1972; Yamamura and Snyder, 1973). Studies described below 
with CHT knockout (-/-) mice demonstrate that HACU is mediated by CHT, whereas 
earlier studies demonstrated that CHT provides the rate-limiting step in ACh synthesis 
(Holden et al., 1975; Jope, 1979b; Kuhar and Murrin, 1978a; Simon and Kuhar, 1975; 
Tucek, 1985a). Consequently, specific inhibition of CHT by HC-3 impairs ACh synthesis  
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Figure 3. High affinity choline uptake is essential to maintain evoked ACh synthesis 
and release. Rat striatal slices were incubated in the presence (HC-3) or absence 
(control) of 5 µM HC-3, a specific inhibitor of CHT-mediated high affinity choline 
uptake. In the presence of HC-3, ACh release could not be sustained during a 15Hz 
electrical stimulation. Adapted from Maire et al. (1983). 
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and release, thus compromising cholinergic neurotransmission (Guyenet et al., 1973; 
Murrin et al., 1977). 
 
Pharmacological and Behavioral Modulation of HACU 
CHT-mediated HACU is highly regulated by neuronal activity (Simon and Kuhar, 
1975), but the molecular mechanisms of this regulation remained unclear until recently. 
Traditionally, [3H]HC-3 ligand binding assays have been used to quantitatively determine 
CHT levels in sealed nerve terminal preparations (synaptosomes) or tissue sections 
(Sandberg and Coyle, 1985b; Vickroy et al., 1985; Vickroy et al., 1984). Using uptake 
and binding techniques, studies have shown that CHT-mediated HACU is regulated by 
neuronal activity in vitro and in vivo (Murrin and Kuhar, 1976). Accordingly, in vivo 
administration of drugs that affect the turnover and release of ACh (both indices of 
cholinergic activity) results in altered HACU and [3H]HC-3 binding measured in vitro. 
For example, intraperitoneal (i.p.) administration of the muscarinic antagonist atropine, 
which induces cholinergic firing and ACh release, leads to increases in HACU Vmax and 
[3H]HC-3 binding in synaptosomes from rat striatum and hippocampus (Goldman and 
Erickson, 1983; Lowenstein and Coyle, 1986). In contrast, treatment with agents that 
inhibit cholinergic signaling, such as pentobarbital, result in lower ACh turnover, HACU, 
and [3H]HC-3 binding (Lowenstein and Coyle, 1986). 
Additional studies have employed behavioral stimuli, such as training to criterion 
in a T maze or an 8 arm radial maze, to activate cholinergic neurons and assess CHT 
response in the whole animal (Burgel and Rommelspacher, 1978; Wenk et al., 1984). The 
data demonstrate increases in synaptosomal HACU Vmax from behaviorally trained versus 
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non-trained animals, remarkably lasting more than 20 days beyond the final training or 
testing session (Wenk et al., 1984). In a modern refinement of these studies, 
Apparsundaram and colleagues have examined CHT-mediated HACU in a behavioral 
paradigm that specifically taxes attentional effort and therefore depends on intact cortical 
cholinergic circuits (Apparsundaram et al., 2005; McGaughy et al., 1996). The authors 
trained rats in a cognitive vigilance task (CVT), which required the animals to detect the 
presence or absence of a light stimulus and respond by making the correct choice 
between two levers. Control animals were either not subjected to the behavioral paradigm 
(non-performing (NP) rats) or were trained in a simple reaction time task (SRTT), where 
only the correct lever was present, thus decreasing demands on attentional processing. 
HACU Vmax in synaptosomes from the right medial prefrontal cortex (mPFC), but not 
striatum, was accelerated in CVT compared to SRTT and NP control rats 
(Apparsundaram et al., 2005). These results support a coupling of cholinergic signaling, 
demonstrated by increased extracellular ACh release in the mPFC of CVT-performing 
rats, and CHT capacity (Arnold et al., 2002). 
Two explanations for a mechanism underlying activity-dependent changes in 
HACU Vmax have been proposed: a change in the intrinsic rate of CHT activity (catalytic 
activation) or a change in the number of CHTs at the plasma membrane (altered 
trafficking). Although changes in [3H]HC-3 binding have commonly been interpreted in 
the literature as an index of changing CHT protein levels, several studies suggest that 
alterations in [3H]HC-3 binding may reflect not only changes in the number of binding 
sites (Bmax) but also affinity for the ligand (KD) (Lowenstein and Coyle, 1986). Studies 
have shown Ca2+-dependent, ATP-induced changes in [3H]HC-3 binding in membrane 
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preparations, which appear to be primarily due to changes in KD (Chatterjee and 
Bhatnagar, 1990; Saltarelli et al., 1990). This interpretation is supported by the use of 
membrane preparations which, unlike synaptosomal sealed nerve terminals, do not 
contain intracellular reserve pools of CHT that can be trafficked to the plasma membrane 
(Chatterjee and Bhatnagar, 1990; Saltarelli et al., 1990). Therefore, any differences in 
[3H]HC-3 binding in membrane preparations are likely the result of conformational 
changes of the CHT protein already present in the plasma membrane, due to 
phosophorylation or other protein modifications. The cloning and characterization of 
CHT have provided new tools, such as CHT-specific antibodies, which can be used to 
affect a more direct and reliable quantification of CHT protein levels at the plasma 
membrane. 
 
Cloning the CHT Gene 
CHT genes have now been identified in Caenorhabditis elegans (Cho-1) (Okuda 
et al., 2000a), torpedo (CTL1) (O'Regan et al., 2000), rat (CHT1) (Okuda et al., 2000a), 
human (hCHT) (Apparsundaram et al., 2000; Okuda and Haga, 2000), and mouse 
(mCHT) (Apparsundaram et al., 2001b). The mCHT cDNA encodes a protein of 580 
amino acids, with a molecular mass of approximately 63 kDa. Sequence analysis of 
mCHT demonstrates a 93% and 98% amino acid identity with the human and rat 
orthologs (Apparsundaram et al., 2001b), and identifies the gene as a member of the 
Na+/glucose solute carrier superfamily 5 (SLC5). Analysis of the amino acid sequence 
predicts a topology of thirteen transmembrane domains, an extracellular consensus site 
for N-linked glycosylation, and several cytoplasmic protein kinase A (PKA) and protein 
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Figure 4. CHT gene and protein structures. (A) The hCHT gene is located on 
chromosome 2 and contains 9 exons. (B) The mCHT cDNA encodes a protein of 580 
amino acids, with a molecular mass of approximately 63 kDa. Analysis of the amino acid 
sequence predicts a topology of thirteen transmembrane domains, an extracellular 
consensus site for N-linked glycosylation, and several cytoplasmic protein kinase A 
(PKA) and protein kinase C (PKC) phosphorylation sites (Apparsundaram et al. 2001a). 
Adapted from Ferguson and Blakely (2004). 
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kinase C (PKC) phosphorylation sites (Fig. 4) (Apparsundaram et al., 2001a); for review 
see (Ferguson and Blakely, 2004). Electron microscopy (EM) immunogold labeling 
studies, using antibodies directed towards COOH-terminal epitopes, support a 
cytoplasmic localization of this domain (Ferguson et al., 2003), whereas epitope-tagging 
efforts confirm an extracellular localization of the N-terminus (Ribeiro et al., 2005). In 
addition to the generation of polyclonal and monoclonal CHT-specific antibodies, the 
cloning of mCHT has led to the generation of a CHT knockout mouse (Ferguson et al., 
2004) – both useful new tools for the study of in vivo CHT function and regulation. 
  
CHT Provides the Molecular Basis of HACU Regulation 
 Prior to the availability of antibodies, [3H]HC-3 autoradiography in brain slices or 
binding in brain membrane preparations was used to assess HACU localization. These 
techniques demonstrated significant overlap between HACU and known cholinergic 
terminals, such as striatum, cortex, and hippocampus (Sandberg and Coyle, 1985a; 
Vickroy et al., 1984). Zahalka et al. (1993) showed that [3H]HC-3 binding in the rat 
cerebral cortex, striatum, and hippocampus generally reached adult levels around the 5th 
to 6th postnatal week (Zahalka et al., 1993).  
The generation of CHT-specific antibodies allowed for the first detailed 
characterization of CHT expression and subcellular localization. Several studies utilizing 
immunoblotting and immunofluorescence have demonstrated that CHT is expressed 
predominantly in cholinergic terminals (Ferguson et al., 2003; Kus et al., 2003; Lips et 
al., 2002; Misawa et al., 2001), although CHT mRNA and protein expression have also 
been detected in human keratinocytes, rat tracheal epithelia, lung bronchial epithelial 
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cells, and human T lymphocytes (Fujii et al., 2003; Kawashima and Fujii, 2003; Pfeil et  
al., 2003b; Proskocil et al., 2004).  
Within cholinergic terminals, where HACU activity predominates and the 
transported choline is specifically targeted for ACh synthesis (Bussiere et al., 2001), CHT 
is localized in at least two distinct pools: an intracellular vesicular pool and a plasma 
membrane pool (Ferguson and Blakely, 2004; Ferguson et al., 2003). Immunogold 
labeling and EM analysis in striatal cholinergic terminals and the NMJ reveal that the 
majority of CHT is present on intracellular small, clear synaptic vesicles (Ferguson et al., 
2003; Nakata et al., 2004). At the NMJ, less than 5% of CHT immunoreactivity is 
associated with the plasma membrane (Nakata et al., 2004). Parallel biochemical 
approaches utilizing subcellular fractionation and velocity gradient purification confirm 
an enrichment of CHT in synaptic vesicles that are also enriched for synaptic vesicle 
proteins such as synaptophysin and VAChT, and can be demonstrated to contain ACh 
(Ferguson et al., 2003). 
The pattern of synaptic vesicle CHT enrichment lends strong support to the 
hypothesis that CHT activity may be regulated, at least in part, by trafficking of CHT 
intracellular reserves to the plasma membrane under conditions of demand on cholinergic 
neurotransmission. Indeed, high potassium in vitro depolarization of striatal 
synaptosomal preparations (which leads to ACh release and hence mimicks in vivo 
neuronal activity) results in increased HACU Vmax, mediated largely, but not entirely, by 
redistribution of CHT from the intracellular reserve pool (Ferguson et al., 2003). 
Interestingly, while all CHT-positive synaptic vesicles also contain VAChT, only CHT 
appears to be retained at the plasma membrane for a period of time following synaptic 
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terminal depolarization (Ferguson et al., 2003). The presence of dileucine-like 
internalization motifs in the cytoplasmic C-terminus of CHT and the transporter’s largely 
intracellular localization suggest that specific mechanisms must exist to allow 
stabilization of CHT at the plasma membrane for prolonged enhancements of HACU. 
Indeed, experimental evidence from site-directed mutagenesis followed by in vitro 
biochemical studies in transfected cell lines, as well as primary neuronal cultures, points 
to clathrin-mediated endocytosis as a highly efficient mechanism for CHT trafficking 
(Ribeiro et al., 2003; Ribeiro et al., 2005). Gates and colleagues have used 
immunoprecipitation, immunoblotting and synaptosomal biotinylation techniques to 
reveal that PKC and protein phosphatase 2A (PP2A) induced alterations in CHT 
trafficking are paralleled by changes in CHT phosphorylation, although specific 
mechanisms linking phosphorylation with trafficking capacity are as yet unclear (Gates et 
al., 2004).  
Finally, the Sarter and Apparsundaram labs elegantly combined in vivo behavioral 
paradigms (specifically taxing attentional cholinergic circuits) with in vitro synaptosomal 
subcellular fractionation (allowing quantification of CHT in the plasma membrane), in 
order to provide an explanation for the changes in HACU Vmax observed following 
behavioral modulation of cholinergic activity (Apparsundaram et al., 2005). The authors 
observed significantly increased density of CHT, but not VAChT or other synaptic 
protein, at the plasma membrane in response to cholinergic activity, but not a control 
behavioral paradigm, that did not challenge cholinergically-supported attentional 
processes specifically. The above studies provide strong evidence for CHT trafficking 
from intracellular reserves to the plasma membrane as the mechanism of CHT regulation 
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currently understood best. Additional studies will be needed to describe the molecular 
detail of possible alternative modes of CHT regulation, including catalytic activation of 
plasma membrane resident CHT proteins. Of note, activation of biogenic amine 
transporters by p38 mitogen-activated protein kinase has recently been described, and 
may provide a model for non-trafficking-based activation of CHT (Apparsundaram et al., 
2001c; Zhu et al., 2004). 
 
CHT and Genetic Mouse Models of Cholinergic Dysfunction 
Genetic approaches have been used to generate mice with over-expression or 
knockouts of various components of the system that supports ACh neurotransmitter 
turnover, including CHT itself, the ChAT and AChE enzymes, and various muscarinic 
and nicotinic receptor subtypes. These mouse models of cholinergic dysfunction have 
provided new evidence for a dynamic role of CHT as a critical modulator of cholinergic 
neurotransmission (for review see Bazalakova and Blakely, 2006). 
 
CHT is Upregulated in the AChE Knockout (AChE-/-) Mouse 
AChE hydrolysis of ACh in the synaptic cleft terminates cholinergic 
neurotransmission. Therefore, a genetically-induced loss of AChE may be viewed as a 
hypercholinergic state, where diminished ACh metabolism leads to sustained cholinergic 
receptor stimulation. While such prolonged receptor activation can be lethal, AChE-/- 
mice survive to adulthood, although they are unable to eat solid food and their lifespan is 
reduced due to fatal seizures (Duysen et al., 2002; Xie et al., 2000). The survival of these 
 15
animals raises two questions: what parameters change to compensate for a state of ACh 
hypometabolism and which genes show the most plastic response? 
Whereas butyrylcholinesterase activity and mRNA levels of muscarinic receptors 
in these mice are not changed, [3H]quinuclinyl benzilate ([3H]QNB) binding studies, 
immunofluorescence, and immunoblotting with specific antibodies demonstrate 50 to 
80% reduced expression of M1, M2, and M4 receptors in AChE-/- cortex and 
hippocampus homogenates, as well as decreased cell surface and increased 
internalization of the muscarinic receptors (Li et al., 2003; Li et al., 2000; Mesulam et al., 
2002; Volpicelli-Daley et al., 2003a). Consequently, AChE-/- mice display reduced 
sensitivity to mAChR stimulation such as oxotremorine-induced hypothermia, tremor, 
salivation, and analgesia, but dose-dependent heightened sensitivity to mAChR 
inhibition, namely scopolamine-induced increases in locomotor activity (Volpicelli-Daley 
et al., 2003b).  
 Intriguingly, immunoblotting for CHT reveals a 60% increase in CHT expression 
in striatal homogenates, in the absence of changes in ChAT activity or VAChT 
expression (Volpicelli-Daley et al., 2003b). This compensatory change may reflect an 
attempt by the presynaptic terminal to increase substrate availability in a cholinergic 
system deprived of choline derived from ACh hydrolysis, which thus appears critical for 
the sustained re-synthesis of releasable neurotransmitter. Apparently, although 
micromolar choline levels are present in blood and CSF, levels at cholinergic terminals 
may be more limited due to efficient clearance mechanisms (including both HACU and 
LACU).  Regardless, AChE-/- phenotypes complement findings in CHT+/- mice which, 
in contrast to AChE-/- animals, have approximately 50% less CHT protein compared to 
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CHT wild type (CHT+/+) siblings, are hypo-sensitive to scopolamine challenge, and are 
hyper-responsive to oxotremorine-induced tremor (Bazalakova et al., 2007). The above 
studies suggest that CHT upregulation and muscarinic receptor downregulation and 
internalization act in concert to provide a mechanism of compensation for decreased ACh 
metabolism in AChE-/- mice. These data also indicate that a mechanism must be in place 
to transduce changes in extracellular levels of ACh to CHT. This feedback mechanism 
could be mediated by presynaptic receptors or a retrograde signal that has yet to be 
identified.     
 
CHT is Also Upregulated in the Acetylcholinesterase (AChE) Transgenic Mouse  
Interestingly, increased CHT protein expression is present in another model of 
cholinergic dysfunction – AChE transgenic (AChE-Tg) mice. Autoradiography in brain 
sections reveals a higher than twofold increase in [3H]HC-3 binding in the striatum of 
AChE-Tg mice compared to wild type controls (Beeri et al., 1997). These findings 
correlate with observations of approximately 70% higher HACU in striatal and 
hippocampal, but not cortical synaptosomal preparations from AChE transgenics (Erb et 
al., 2001). Whereas microdialysis revealed normal basal levels of extracellular ACh in 
the hippocampi of freely moving AChE-Tg mice, halothane anaesthesia reduced both 
ACh levels and synaptosomal HACU to significantly lower levels in AChE transgenics 
compared to wild type controls. In addition, administration of the AChE inhibitor 
physostigmine (i.p.) normalized the higher HACU observed in AChE transgenics to 
control levels (Erb et al., 2001). Although it may appear paradoxical that CHT is 
upregulated in both AChE-Tg and AChE-/- mice, CHT upregulation in the AChE-Tg 
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brain may serve as an attempt to compensate for overall cholinergic hypofunction caused 
by hypermetabolism of ACh. 
Whereas initial studies reported unchanged tritiated ligand-binding for nAChRs 
and mAChRs in brain sections (Beeri et al., 1997), subsequent studies detected increased 
[3H]cytosine (α4 nAChR subunit) and [3H]AF-DX-384 (M2 mAChR subtype) binding in 
homogenates from AChE transgenic striata. No changes were observed in [125I]α-
bungarotoxin (α7 nicotinic receptor subunit) or [3H]pirenzepine (M1 muscarinic receptor 
subtype) binding (Svedberg et al., 2003). The specific changes in CHT, mAChR, and 
nAChR expression suggest that these proteins work concurrently to overcome insults on 
cholinergic signaling in AChE transgenics, a strategy for compensation comparable to 
that observed in AChE-/- mice.  
Altered expression of CHT and cholinergic receptors may underlie differences in 
behavior and sensitivity to pharmacological challenges by the AChE-Tg mice. Similarly 
to AChE-/- animals, AChE transgenics are resistant to muscarinic (oxotremorine) 
agonist-induced hypothermia, as well as nicotinic (nicotine) agonist-induced 
hypothermia, but retain their ability to thermoregulate as evidenced by normal responses 
to noradrenergic agents and exposure to cold (Beeri et al., 1995). AChE transgenics 
display normal motor behavior in familiar environments (repeated exposure to open field 
paradigm), but increased motor activity in novel environments (initial exposure to open 
field chambers) (Erb et al., 2001), and are impaired in an age-dependent manner in both 
visible and hidden versions of the water maze (Beeri et al., 1995). 
In summary, the findings of increased [3H]HC-3 binding and HACU in AChE 
transgenics suggest that CHT upregulation provides one compensatory mechanism in a 
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hypocholinergic state due to excess ACh metabolism, possibly in conjunction with 
altered muscarinic and/or nicotinic receptor expression.   
 
CHT Upregulation Provides Mechanism of Compensation in Choline Acetyltransferase 
Heterozygous (ChAT+/-) Mice  
 Upregulation of CHT protein expression and function have also been observed in 
ChAT+/- mice. While ChAT activity is reduced by almost 50% in the ChAT+/- brain, 
both bulk ACh levels in the striatum, frontal cortex, and hippocampus, as well as high 
potassium depolarization-induced ACh release from ChAT+/- hippocampal slices, are 
normal. Not surprisingly, ChAT+/- performance in the water maze paradigm is 
indistinguishable from that of ChAT+/+ controls (Brandon et al., 2004). 
 How, then, is functional compensation achieved in the ChAT+/- animals? The 
authors report that AChE activity is comparable between ChAT+/- and ChAT+/+ mice, 
and while they do not investigate muscarinic or nicotinic receptor expression, reverse-
transcriptase polymerase chain reaction and immunoblotting reveal 70% and 150% 
increases in CHT mRNA (septum) and protein (striatum, cortex, hippocampus, spinal 
cord) respectively. In addition, in vitro [3H]ACh synthesis in hippocampal slices pre-
loaded with [3H]choline substrate was approximately 60% higher in ChAT+/- tissues 
compared to ChAT+/+ controls (Brandon et al., 2004). The above studies point to CHT 
upregulation as an essential, compensatory response to the reduction in ChAT activity, 
sustaining wild type levels of AChE activity, as well as ACh content and depolarization-
evoked ACh release. Clearly, cholinergic neurons place a significant responsibility on 
CHT to balance deficits elsewhere in cholinergic signaling.  
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CHT Downregulation in α3 Nicotinic Receptor Knockout (α3-/-) Mice 
  The α3-/- mice provide the first illustration of CHT regulation as a compensatory 
response to altered cholinergic receptor function (Rassadi et al., 2005). 
Electrophysiological recordings from cholinergic sympathetic superior cervical ganglia in 
α3-/- mice demonstrate that absence of postsynaptic α3 receptors completely disrupts fast 
excitatory synaptic transmission. Immunofluorescence, confocal microscopy, and EM 
analyses demonstrate unaltered terminal localization of various synaptic proteins, 
including ChAT, VAChT, synaptobrevin, syntaxin 1a, and synaptotagmin, as well as the 
morphologic integrity of the cholinergic synapses under investigation, including normal 
levels of small clear synaptic vesicles, large dense core vesicles, docked vesicles, 
synaptic cleft width, etc. Instead, the authors identify the basis of the electrophysiological 
phenotype as a deficit in presynaptic ACh release.  
Electrophysiological recordings reveal that repeated stimulation results in faster 
depletion of neurotransmitter in α3-/- terminals compared to α3+/+ controls. 
Remarkably, HC-3 blockade has no effect on α3-/- ACh release, whereas it significantly 
reduces α3+/+ ACh output, providing further support for the hypothesis that CHT 
downregulation provides a compensatory mechanism at α3-/- sympathetic ganglia 
synapses (Rassadi et al., 2005). It will be informative to use choline uptake, 
immunoblotting, and immunofluorescence approaches to assess potential loss of CHT 
function and expression as a conclusive mechanism by which ACh release capacity is lost 
in α3-/- mice. The findings in α3-/- synapses again point to the likely existence of a 
retrograde signal, whose ultimate target is regulation of CHT function and expression.
 In summary, studies in various genetic mouse models of cholinergic dysfunction 
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point to CHT as a predominant presynaptic modulator of functional compensation. For 
example, while VAChT and ChAT function and expression are unaltered, CHT is 
functionally upregulated to sustain cholinergic transmission in AChE Tg mice. CHT 
upregulation is the only biochemical variable that is different between ChAT+/+ and 
ChAT+/- mice, while CHT downregulation in α3 knockouts stands in stark contrast to 
wildtype expression and localization of various other presynaptic proteins, including 
ChAT, VAChT, synaptobrevin, syntaxin 1a, and synaptotagmin. Thus, studies of CHT 
function and regulation, including characterization of CHT knockout and heterozygous 
mice, are expected to provide valuable insight into mechanisms of signaling and 
compensation at the cholinergic synapse, cholinergic transmission in the whole organism, 
and a valuable new model of cholinergic dysfunction. 
 
Significance  
ACh is a neurotransmitter of key importance in both central and peripheral 
nervous systems (Iversen et al., 1975). ACh maintains vital biological functions such as 
motor function, memory, cognition, and autonomic regulation. Selective blockade of the 
rate-limiting step in ACh synthesis - CHT-mediated HACU - reduces ACh synthesis and 
release in vitro (Maire and Wurtman, 1985) and impairs cholinergic function in vivo 
(Schueler, 1955) demonstrating the essential physiological role of CHT. CHT-mediated 
HACU is highly regulated by neuronal activity (Simon and Kuhar, 1975), but the 
molecular mechanisms of this regulation are not clear. The recent cloning of CHT has 
allowed our lab to generate new, valuable tools, including specific anti-CHT antibodies 
and a CHT knockout mouse. The studies described here use these tools towards a first 
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direct demonstration of requirements for CHT in vivo, both under basal conditions and in 
response to behaviorally-activated cholinergic neurotransmission. The outlined 
experiments also extend previous studies, which have used less direct ligand-binding 
approaches to study CHT trafficking in pharmacologically-activated cholinergic 
signaling. The experimental results address the possibility of a pre-synaptic, CHT-
mediated, molecular plasticity mechanism, regulated by and needed to sustain in vivo 
cholinergic activity.  
In addition, characterizations of basal or induced phenotypes in CHT+/- mice 
suggest and will continue to direct new insights into the possible role of CHT in human 
disorders of known cholinergic dysfunction such as Alzheimer’s disease (Coyle et al., 
1983), Parkinson’s disease (Calabresi et al., 2000), schizophrenia (Tandon, 1999), 
Huntington’s disease (Lange et al., 1992), and dysautonomia (Baron and Engler, 1996). 
Furthermore, these studies can help identify disorders where CHT contributions have not 
been recognized so far. Better understanding of CHT function and regulation will allow 
manipulation of cholinergic signaling in vivo and suggest approaches to CHT as a target 
for therapy in disease. 
 
Thesis Objectives  
We have developed CHT-/- and CHT+/- mice which offer the valuable 
opportunity to study CHT in a whole animal model and provide a more physiologically 
relevant environment than ex vivo systems. Therefore, the experiments proposed here use 
CHT-/-, CHT+/-, and CHT+/+ animals and combine biochemical, pharmacological, and 
behavioral approaches to directly test the central hypothesis: CHT is essential for ACh 
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synthesis and release in response to sustained demands on cholinergic signaling, and 
in turn supports behaviors dependent on cholinergic signaling.  Three specific aims 
were pursued to test the central hypothesis: 
 Specific Aim 1. Establish the physiological importance and the consequences 
of genetic ablation of CHT in vivo. Hypothesis: As the rate-limiting step of ACh 
synthesis, CHT is essential for cholinergically-supported physiological processes. To test 
this hypothesis I characterized morphological and biochemical phenotypes of CHT 
knockout (-/-) mice. 
 Specific Aim 2. Assess dependence of ACh turnover and CHT regulation on 
CHT expression. Hypothesis: Diminished intracellular reserve pools of CHT, the rate-
limiting step of ACh synthesis, will alter ACh synthesis and/or release in response to 
sustained cholinergic neurotransmission. To test this hypothesis I evaluated ACh and 
choline levels in brain homogenates from CHT+/+, CHT+/-, and CHT-/- mice, and used 
biochemical approaches (HC-3 binding, synaptosomal biotinylation, AChE and ChAT 
activities, and muscarinic receptor immunoblotting) to investigate the mechanisms of 
CHT regulation and compensation in the CHT+/- brain. 
 Specific Aim 3. Investigate the role of CHT in animal behavior dependent on 
cholinergic signaling. Hypothesis: Reduced CHT pools likely result in cholinergic 
dysfunction and compromise behavior dependent on cholinergic signaling in CHT+/- 
mice. To test this hypothesis I compared basal and/or challenge-induced performances of 
CHT+/- and CHT+/+ siblings in sensory-motor, anxiety, cognitive, cardiovascular, 
addiction, and circadian rhythms behavioral paradigms. 
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CHAPTER II 
 
GENETIC ABLATION OF CHT IS LETHAL – STUDIES IN  
CHT KNOCKOUT (CHT-/-) MICE 
 
Introduction 
Acetylcholine (ACh) serves important roles as a neurotransmitter of both the 
central and peripheral nervous systems. ACh is released at the neuromuscular junction 
(NMJ), as well as at autonomic synapses, and also modulates a variety of central circuits 
that support arousal, attention, reward, learning, and memory (Dani, 2001; Laviolette and 
van der Kooy, 2004; Wess, 2004; Winkler et al., 1995). Lethal deficits in cholinergic 
function occur with exposure to irreversible acetylcholinesterase (AChE) inhibitors 
(Hardman and Limbird, 2001). Genetic and autoimmune impairments in ACh synthesis 
or responsiveness at the NMJ trigger myasthenic syndromes (Engel et al., 2003), whereas 
degeneration of basal forebrain cholinergic neurons occurs in Alzheimer’s disease and 
may contribute to dementia (Whitehouse et al., 1982). In turn, both myasthenias and 
symptoms of dementia are relieved by reversible AChE inhibitors (Doody, 2003).  
Within presynaptic terminals, ACh is synthesized from choline and acetyl-CoA by 
the enzyme choline acetyltransferase (ChAT) (Brandon et al., 2003; Misgeld et al., 2002), 
and this ACh synthesis is thought to be limited by choline availability (Jope, 1979a; 
Tucek, 1985b). With respect to sources of choline, pathways exist within the brain for the 
de novo synthesis of phosphatidylcholine from phosphatidylethanolamine (Blusztajn and 
Wurtman, 1981), and the release of choline by the action of phospholipase D can support 
ACh synthesis (Lee et al., 1993). However, cytoplasmic synthesis of ACh is believed to 
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depend predominantly on the acute uptake of extracellular choline across the presynaptic 
plasma membrane (Birks and MacIntosh, 1961; Jope, 1979a). Two major neuronal 
transport mechanisms for choline have been described: a Na-dependent, hemicholinium-3 
(HC-3)-sensitive, high-affinity choline uptake (HACU; Km = 1–5 µM) process 
associated with cholinergic presynaptic terminals and a more ubiquitous mechanism of 
HC-3-insensitive, Na-independent, choline transport having a lower affinity for choline 
(Km = 100 µM) (Haga, 1971; Yamamura and Snyder, 1972). High-affinity HC-3-
sensitive choline transport is believed to sustain ACh synthesis in presynaptic terminals 
(Birks and MacIntosh, 1961; Guyenet et al., 1973; Haga, 1971). Indeed, the dynamic 
regulation of HACU in response to changes in cholinergic neuronal activity appears to 
match presynaptic ACh synthesis to the rate of ACh release (Kuhar and Murrin, 1978b). 
Despite several decades of research on presynaptic cholinergic mechanisms, the 
identity of the choline transporter (CHT) has only recently become clear (Ferguson and 
Blakely, 2004). Okuda and coworkers (Okuda et al., 2000b), as well as our own group 
(Apparsundaram et al., 2001b; Apparsundaram et al., 2000), have shown that the 
transfection of cloned CHT cDNAs elicits Na/Cl -dependent HC-3-sensitive HACU in 
cultured cells. Additionally, in rodents (Ferguson et al., 2003; Misawa et al., 2001) and 
humans (Kus et al., 2003), CHT proteins are found in all major cholinergic nuclei and 
colocalize with the vesicular ACh transporter (VAChT) at presynaptic terminals 
(Ferguson et al., 2003). In conjunction with evidence that HC-3 treatment of animals 
suppresses ACh synthesis (Freeman et al., 1979; Schueler, 1955), CHT’s synaptic 
localization argues that the transporter plays a critical role in sustaining cholinergic 
signaling. 
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To evaluate the in vivo contributions of CHT to cholinergic neurotransmission, 
we targeted the CHT gene in mice by homologous recombination in embryonic stem (ES) 
cells. CHT-/- mice exhibited deficits in cholinergic function and died neonatally. In 
contrast, CHT+/- mice maintain wild-type levels of HC-3-sensitive presynaptic choline 
uptake despite a significant reduction in CHT protein levels (Chapter III). Our results 
demonstrate that CHT plays an essential and regulated role in sustaining cholinergic 
neurotransmission. 
 
Materials and Methods 
 
Gene Targeting 
Approval was obtained from our respective Institutional Animal Care and Use 
Committees for experiments involving mice. A portion of the mouse CHT gene 
beginning at the start codon in exon 2 and extending into intron 4 was deleted by 
homologous recombination in embryonic stem cells. To generate genomic fragments 
suitable for a CHT-targeting vector, we used PCR with Platinum Pfx DNA polymerase 
(Invitrogen) or the Expand long Template PCR System (Roche, Indianapolis, IN) and 
129SvEvTacBr genomic DNA to amplify a 3-kb segment (short arm) extending from the 
CHT promoter region to the start codon in exon 2 and a 5-kb fragment (long arm) 
beginning in intron 4 from mouse genomic DNA. The DNA encoding enhanced green 
fluorescent protein (EGFP), including 3' untranslated region, was amplified from the 
plasmid pEGFP-N2 (BD Biosciences, San Jose, CA). The oligonucleotide primers used 
in the PCRs included the addition of restriction enzyme cutting sites and/or loxP sites to 
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facilitate subsequent subcloning, targeting vector construction, and marker excision. The 
ligation of the PCR products into the vector pFLP-NTK (courtesy of Mark Magnuson, 
Department of Molecular Physiology and Biophysics, Vanderbilt University) yielded the 
final targeting construct that included loxP sites flanking the EGFP and FLP recognition 
target (FRT) sites flanking the phosphoglycerol kinase promoter-driven neomycin (NEO) 
gene cassette (Fig. 5A). This targeting construct also included a 3' thymidine kinase gene 
driven by a phosphoglycerol kinase promoter to allow for negative selection. 
For targeting of the mouse CHT (mCHT) gene, the linearized targeting vector was 
electroporated into TL-1 129SvEvTacBr embryonic stem (ES) cells and recombination 
was selected for with G418 and ganciclovir (Vanderbilt Transgenic Mouse/ES Cell 
Shared Resource). Southern blotting was used to screen » 380 surviving ES cell colonies, 
and 1 positive recombined clone was identified. The selected ES cells were injected into 
C57BL/6 blastocysts and after transfer into a surrogate mother, seven chimeric animals 
were born. The amount of chimerism ranged from 20% up to 95% and two lines have 
been established from the most chimeric animals. The results described in this report 
derive from experiments on mice carrying NEO and EGFP at the CHT locus on a mixed 
129SvEvTacBr × C57BL/6 genetic background. Each replication of an individual 
experiment involved littermates of the reported genotypes to minimize differences in 
genetic variability. 
To improve EGFP expression that could be limited by the adjacent NEO 
transgene (Pham et al., 1996), and rule out any toxic effects of NEO expression at this 
locus, we also excised the NEO cassette by breeding one line to FLP transgenic mice 
(Rodriguez et al., 2000). Studies on lines with excised markers yielded initial results that 
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appear identical to those of our studies with the nonexcised lines. Finally, the EGFP 
expression is also unlikely to contribute our phenotypes as much higher, directly 
detectable levels of transgenic EGFP expression have been reported in motor neurons 
without causing neuronal dysfunction (Feng et al., 2000). 
 
Mouse Genotyping  
For Southern blotting, mouse tail DNA was digested with EcoRV (New England 
Biolabs), separated on 0.9% agarose gels, and transferred to Zetaprobe nylon membranes 
(Bio-Rad). A 5' external probe was generated by PCR with 5'-
CCAGGATCTAGACCAACTCG-3' and 5'-TGAAAGACGACCTGAGGTAG-3' as 
oligonucleotide primers, followed by EcoRV digestion and random-priming 32P labeling 
of the resulting 1-kb fragment (Fig. 5B) Genotyping by PCR was performed using a 
common WT and KO sense oligonucleotide primer: (96 bp 5' of ATG of CHT, 5'-
AGTGCGTGGCTGCTTAAT-3'), a WT antisense primer (841 bp from above primer in 
WT allele, 5'-AGATGATGGCCTGTGAATTC-3'), and a KO reverse primer (401 bp 
from sense primer in EGFP of the KO allele, 5'-TTGAAGAAGATGGTGCGCTC-3') 
(Fig. 5C) and Taq DNA polymerase (Promega) with extracted tail DNA as template. 
 
Immunofluorescence and Histochemical Analyses  
Immunofluorescent labeling of floating brain sections and neuromuscular junction 
preparations was based on previously described protocols (Schroeter et al., 2000). We 
have previously characterized the anti-CHT antibodies used in this study (Ferguson et al., 
2003). Commercially available antibodies and fluorescent probes included mouse 
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monoclonal neurofilament antibody (Sternberger Monoclonals, Lutherberg, MA), goat 
anti-ChAT polyclonal antibody (Chemicon, Temecula, CA), rabbit polyclonal anti-GFP, 
Alexa-660-phalloidin and Alexa-488-a -bungarotoxin (BgTx) (Molecular Probes). 
Secondary antibodies were obtained from Jackson ImmunoResearch. 
Acetylcholinesterase histochemistry was performed by the method of Karnovsky and 
Roots (Karnovsky and Roots, 1964). Bright-field images were captured on an Olympus 
BX50WI microscope with Kodak Elite 160 film. Confocal analysis was performed with 
an Axioplan 2 confocal imaging system equipped with internal He/Ne and external Ar/Kr 
lasers with output at 488, 568, and 660 nm (Vanderbilt University Medical Center Cell 
Imaging Core Resource). Z-series were collected by optical sectioning at an interval of 1 
um. Quantitative analyses of digital images were performed with METAMORPH 
software (Universal Imaging).  
 
Immunoblot Analysis   
Freshly dissected brain tissue was homogenized in 0.32M sucrose-5mM Hepes-
NaOH pH 7.4 supplemented with a protease inhibitor cocktail (Sigma, St. Louis, MO) 
with a Potter Elvejhem homogenizer (8 strokes at 500 rpm).  After determining and 
adjusting protein concentration, the homogenate was diluted with sample buffer to yield 
1% sodium dodecyl sulfate (SDS), 31.25 mM TRIS pH 6.8, 5% glycerol, 200mM 2-
mercaptoethanol).  The samples were then resolved by SDS-polyacrylamide gel 
electrophoresis (PAGE), transferred to polyvinylidine difluoride membranes and 
subjected to immunoblot analyses with CHT-specific monoclonal and polyclonal anti-
CHT antibodies (Kus et al., 2003).  Anti-VAChT immunoblots employed a goat 
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polyclonal antibody from Chemicon (Temecula, CA). 
 
Transport Assays   
Crude synaptosomes (P2 fraction) from the brains of newborn mice were prepared 
as previously described for adult mice (Ferguson et al., 2003). All comparisons made 
between CHT genotypes were performed using male littermates. Assays of choline 
transport activity in the brains of newborn mice were performed for 5 minutes at 37 °C in 
Kreb’s Ringer’s Hepes buffer (KRH, 130mM NaCl, 3mM KCl, 2.2mM CaCl2, 
1.2mM MgSO4, 1.2mM KH2PO4, 10 mM glucose, 10mM HEPES, pH 7.4) with a final 
[choline] of 100 nM (specific activity: 83 Ci/mmol, Amersham).  1 µM HC-3 was used to 
define CHT-mediated choline uptake.  For γ-aminobutyric acid (GABA) uptake assays, 
samples were incubated in parallel with 50 nM [3H]-GABA at either 37ºC or 4°C ([3H]-
GABA, 93 Ci/mmol, NEN Perkin Elmer Life Science, Boston, MA).  Assays were 
terminated by aspiration and washing onto polyethyleneimine coated glass fiber filters 
using a Brandel Cell Harvester (Gaithersburg, MD).  The low yield of tissue from the 
newborn mouse brain precluded analysis of saturation kinetics in these samples.  
Analysis of saturation kinetics for choline uptake in whole brain synaptosomes from the 
adult CHT+/- and +/+ littermates was performed as previously described (Ferguson et al., 
2003). 
 
HC-3 Binding Assays   
Membrane preparations were prepared by lysing crude synaptosomes in the P2 
fraction with a Potter Elvejhem homogenizer (5 strokes at 900 rpm) in 5mM Hepes-
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NaOH pH 7.4.  Membranes were collected by centrifugation at 15 000 x g for 20 minutes 
and resuspended in 50mM Tris, 200mM NaCl pH 8 (TRIS-NaCl).  The membranes were 
washed by centrifugation at 15 000 x g and resuspension in TRIS-NaCl.  The binding 
assay used 250-400 µg protein per sample and was performed for 45 minutes at room 
temperature in TRIS-NaCl in the presence of 10nM [3H]-HC-3 (128 Ci/mmol, NEN 
Perkin Elmer Life Science) as per a previously described protocol (Sandberg and Coyle, 
1985a). This concentration of [3H]-HC-3 exceeds the Kd for binding to mCHT 
(Apparsundaram et al., 2001b) and thus represents a measure of the number of HC-3 
binding sites in the preparation.  Specific binding to CHT was defined by parallel assays 
that included 1 µM unlabeled HC-3 or 2 mM choline as competitors of [3H]-HC-3 
binding. 
 
ChAT Activity  
Activity of the choline acetyltransferase (ChAT) enzyme in brain tissue 
homogenates was measured by the synthesis of [14C] acetylcholine (ACh) from [acetyl-1-
14C]-acetyl-coenzyme A and choline.  The newly synthesized [14C] acetylcholine was 
separated from the precursor [acetyl-1-14C]-acetyl-coenzyme A by sodium 
tetraphenylboron extraction (Frick et al., 2002). 
 
Analysis of ACh Levels 
ACh levels in brain tissue were quantified using a liquid chromatography/mass 
spectrometry (LC/MS) approach. The internal standard propionylcholine was added to 
brain tissue microwaved for AChE inactivation (Bertrand et al., 1994), followed by 
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homogenization in acetonitrile, heptane lipid removal, and vacuum drying.  The samples 
were resuspended in mobile phase and ACh was quantified using standard LC/MS 
protocols described previously (Koc et al., 2002) (Vanderbilt Mass Spectrometry Core 
Resource).  Additional assays were performed using high pressure liquid chromatography 
(HPLC) methods (Damsma et al., 1985) with electrochemical detection and achieved 
similar results. 
 For the analysis of ACh synthesis in brains of P0 mice, 400 µm slices from the 
whole brain were preincubated for 10 minutes at 37°C in KRH with or without 10 µM 
HC-3 prior to the addition of [3H]-choline (final concentration 100 nM).  After 30 
minutes the slices were washed and the newly synthesized [3H]-ACh was extracted by 
sonication in acetonitrile.  The samples were centrifuged to pellet cellular debris and the 
supernatant was collected.  This ACh containing supernatant (1 ml) was further purified 
by adding 500 µl heptane, mixing and centrifuging for 15 minutes at 15,000 x g.  The 
resulting heptane layer (upper) was discarded.  The remaining acetonitrile layer was 
vacuum-dried and resuspended in 100 µl 50 mM HsPo4.  50 µl were subjected to HPLC 
in order to separate ACh from choline, as defined by preinjected standards.  20x500 µl 
fractions (flow rate 1ml/min) were collected and subjected to liquid scintillation 
spectrometry.  
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Results 
 
Confirmation of Targeting Strategy 
 Using our previous elucidation of the mCHT coding sequence as a reference point 
(Apparsundaram et al., 2001b) we searched the Celera Discovery System and GenBank 
databases to define the organization of the mCHT gene, including exon and intervening 
intronic sequences. The mCHT gene is encoded by nine exons and spans a 27-kb interval 
on chromosome 17 (GenBank accession no. for genomic contig containing the mCHT 
gene: NT_039656). Our targeting strategy (Fig. 5A) resulted in the deletion of an » 5-kb 
segment of the CHT gene, originating at the start codon in exon 2 and extending into 
intron 4. This deleted sequence was replaced with an EGFP-NEO cassette, with the 
EGFP reporter placed in frame with the endogenous CHT start codon to drive EGFP 
expression in cholinergic neurons and the NEO cassette in the opposite orientation. 
Southern blotting and PCR analyses indicate the successful completion of this targeting 
strategy (Fig. 5 B and C).  
Further confirmation of successful CHT gene disruption is evident with the loss of 
CHT protein from whole-brain extracts (Fig. 5D). The CHT immunoreactivity present in 
distinct cholinergic neurons and fibers is also abolished in the CHT–/– CNS (Fig. 5 E and 
F, respectively). We observe comparable losses of CHT expression by using previously 
characterized polyclonal and monoclonal anti-CHT antibodies (Ferguson et al., 2003). 
Because the anti-CHT antibodies used in these experiments detect epitopes in the distal C 
terminus of the CHT protein, the absence of CHT immunoreactivity also indicates an 
absence of truncated CHT protein.  
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Fig. 5. CHT targeting construct and expression. (A) The mouse CHT gene was 
disrupted by replacing the coding region of exons 2–4 with EGFP and NEO cassettes. 
The EGFP coding sequence is in frame with the endogenous CHT start codon and is 
flanked by loxP sites (L). The NEO cassette is flanked by FRT sites (F). Also indicated 
are the locations of the Southern blotting probe and the PCR products used in the 
genotyping of mice. This diagram depicts five of the nine exons comprising the mouse 
CHT gene. (B) Southern blot detection of the 8- and 6-kb WT and KO alleles, 
respectively. (C) Our PCR-based genotyping strategy detects a WT product of 841 bp 
and a KO product of 401 bp. (D) Immunoblot detection of CHT protein in extracts from 
the whole brains of newborn mice reveals a reduction of CHT protein levels in the +/– 
mice and an absence of CHT immunoreactivity in the –/– mice. (E) 
Immunohistochemistry demonstrates loss of CHT immunoreactivity from cholinergic 
striatal interneurons in CHT–/– mice at birth. (F) CHT immunoreactivity is present in 
facial nucleus motor neuron somata and fibers in a CHT+/– brain (E19) but not in the 
facial nucleus of a CHT–/– littermate. (G) EGFP immunoreactivity (red) overlaps 
(yellow) with ChAT-positive (green) cholinergic neurons in the basal forebrain of an 
adult CHT+/– mouse but is not detected in a +/+ littermate. (Scale bars = 40 µ m in E–
G.). Shawn Ferguson, Valentina Savchenko, and Jane Wright contributed to this figure. 
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Furthermore, our strategy resulted in the expression of EGFP in cholinergic 
neurons, as demonstrated by colocalization of EGFP with ChAT in cholinergic neurons 
of the basal forebrain of an adult CHT+/– mouse (Fig. 5G). EGFP levels are not 
sufficiently high in these cholinergic neurons to allow direct visualization of EGFP 
fluorescence, but reporter expression is clearly detected by using indirect 
immunofluorescence approaches. Our targeting strategy also flanked the EGFP sequence 
with loxP sites and the NEO cassette by FRT sites, to allow for their subsequent removal 
by Cre and Flp recombinase, respectively. In the offspring arising from the mating of 
CHT+/– mice and Flp mice the only difference that we have observed resulting from the 
removal of the NEO cassette is an increase in the expression of EGFP as detected by 
immunofluorescence analysis (data not shown). This may reflect a recognized effect of 
the NEO cassette in suppressing the expression of neighboring genes (Pham et al. 1996) 
and confirms that the phenotypes we observe are most likely due to the loss of CHT 
expression rather than a toxic effect arising from the NEO cassette. 
 
CHT Is Essential for Neonatal Viability 
Validation of our successful disruption of the mouse CHT gene is included in Fig. 
5. In 35 litters produced from the mating of CHT+/- mice, we obtained the expected 
Mendelian ratios in the genotypes of the 242 pups analyzed at E19 or the day of birth (55 
CHT+/+, 117 CHT+/-, and 70 CHT-/-, P=0.35 by χ2 analysis). Newborn CHT-/- pups 
were morphologically normal (Fig. 6A) and equal in weight compared with their healthy 
CHT+/+ and CHT+/- littermates (1.22 ± 0.02 g versus 1.20 ± 0.03 g, n = 10 and 13, 
respectively). Further gross analysis of various organs, including brain, heart, stomach, 
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liver, and kidney, revealed no significant differences in weights or morphologies between 
genotypes. For example, at E19 we observed brain weights of 68 ± 5 mg, 65 ± 4 mg, and 
74 ± 3 mg for (n = 6), (n = 9), and (n = 5) pups (ANOVA P > 0.05). We did not observe 
the hunched back or other symptoms of flaccid paralysis reported for newborn ChAT-/- 
mice (Brandon et al., 2003; Misgeld et al., 2002). With respect to the CNS, Nissl staining 
of brain sections did not reveal any obvious defects in brain development (data not 
shown).  
In the minutes following birth, CHT-null mice became distinguishable from their 
littermates as they were immobile and could only respond with a limited contraction 
when touched. Breathing was sporadic and occurred as single gasps separated by bouts of 
prolonged apnea. These pups became visibly cyanotic and did not often survive beyond 
the first hour (Fig. 6A). Histological examination of the lungs of the CHT-/- pups 
revealed fewer aerated alveoli compared with +/+ littermates (Fig. 6B). The diminished 
aeration of alveoli in lungs from CHT-/- mice affected their buoyancy such that whereas 
CHT+/+ or +/- lungs floated, the CHT-/- lungs sank when placed in aqueous solutions 
(data not shown). These findings support the hypothesis that CHT-/- mice die as a result 
of hypoxia arising from a failure of neurotransmission at the NMJs of the diaphragm and 
intercostal muscles that support respiration. In our analysis of hematoxylin- and eosin-
stained sections of CHT-/- embryos and pups we did not observe any other differences in 
gross organ development or morphology. For example, unlike the ChAT-/- mice 
(Misgeld et al., 2002), the CHT knockouts did not exhibit herniation of the diaphragm. 
We attempted to rescue the CHT knockouts by enriching the diets of the pregnant 
dams throughout gestation with choline-supplemented chow (4 g/kg or 10 g/kg versus the  
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Fig. 6. CHT mediated choline uptake is essential for postnatal viability. (A) Although 
the two pups are equal in size, the CHT–/– pup is visibly cyanotic compared with its 
CHT+/+ littermate (photo taken 30 min after birth). (B) Consistent with the breathing 
defect in CHT–/– mice, lungs from these animals contain fewer inflated alveoli than their 
+/+ littermates. (C) HC-3-sensitive choline uptake (inhibited by 1 µM HC-3) is lost in 
synaptosomes from CHT–/– mice compared with healthy littermates (mean ± SEM of 
measurements made in triplicate). The HC-3-sensitive choline uptake for three CHT–/– 
mice (from separate litters) was compared with eight healthy littermates (six CHT+/– and 
two CHT+/+). The remaining HC-3-sensitive uptake in the CHT–/– mice was not 
significantly different from 0 (t test, P = 0.2). In contrast, uptake of [3H]GABA was 
unimpaired in synaptosomes from the CHT–/– mice. (D) No significant difference 
(ANOVA, P > 0.05) in whole-brain ChAT activity was observed between CHT 
genotypes (mean ± SEM of assays performed in triplicate on samples from 8 +/+,16 +/–, 
and 11–/– mice). (E) ACh levels as detected by LC/MS were not different (ANOVA, P > 
0.05) in either forebrain or hindbrain extracts for any of the CHT genotypes (mean ± 
SEM, n = 4 +/+, 5+/–, and 5–/–). (F) HC-3-sensitive synthesis of [3H]ACh from 
[3H]choline is detected in CHT+/+ brain slices (E19 or newborn, n = 3, *, P < 0.05, 
Student's t test). (G) The HC-3-senstive component of ACh synthesis is absent from 
CHT–/– brain slices (n = 3 mice for each genotype, *, P < 0.05, Student's t test). Shawn 
Ferguson contributed to this figure. 
 39
normal 1 g/kg, Testdiet, Richmond, IN) alone or in combination with choline-
supplemented water (25 mM or 125 mM plus 50 mM saccharin). Similar choline 
supplementation of diets during pregnancy has been reported to have an impact on the 
developing cholinergic system (Cermak et al., 1998; Garner et al., 1995). However, these 
dietary manipulations failed to enhance the survival of the CHT-knockout pups (data not 
shown). We also attempted to rescue newborn CHT   pups by limiting the degradation of 
ACh. Newborn mice were injected sequentially with physostigmine (500 g/kg i.p.) and 
neostigmine (5 mg/kg intramuscular). Signs of cholinergic hyperactivity (splay posture 
and urination) were evident in the control littermates (n = 4) but not in the CHT-/- mice 
(n = 3), yet these treatments failed to noticeably prolong survival of the knockouts (data 
not shown). 
 
Loss of HC-3-Sensitive Choline Uptake and ACh Synthesis in CHT CNS  
To test whether CHT is solely responsible for HC-3-sensitive HACU in the brain, 
we measured rates of [3H]choline uptake into synaptosomes prepared from whole 
newborn mouse brains. As shown in Fig. 6C, CHT-/- synaptosomes failed to accumulate 
[3H]choline in a HC-3-sensitive manner, but they were otherwise normal, as they did not 
differ from samples prepared from littermates with respect to the uptake of [3H]GABA 
(Fig. 6C). The loss of CHT expression also did not appear to affect the viability of 
cholinergic neurons as revealed by assays of forebrain ChAT activity (Fig. 6D). 
Surprisingly, measurements of bulk tissue ACh levels, in either hindbrain or forebrain 
extracts from E19 mice, did not reveal a difference between any of the three genotypes 
(Fig. 6E). We hypothesized that CHT-/- mice may acquire these ACh stores under 
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conditions of low demand on the cholinergic system during development, but might not 
be able to rapidly synthesize ACh via synaptic pathways overseen by CHT. To monitor 
de novo synthesis and storage of ACh, we tested the ability of CHT-/- brain slices to 
synthesize [3H]ACh from [3H]choline in vitro. We observed an HC-3-sensitive pool of 
ACh synthesis in the CHT+/+ samples (Fig. 6F) but not in the slices from the CHT-/- 
mice (Fig. 6G). These results reveal a specific deficit in HC-3-sensitive ACh synthesis in 
CHT mice.  
 
CHT-/- NMJs Cannot Sustain ACh Release 
The lethal phenotype in CHT-/- is consistent with a deficit in ACh release at 
NMJs as a result of the elimination of presynaptic choline uptake. To directly test this 
hypothesis, cholinergic neurotransmission was assessed by using in vitro preparations of 
the sternomastoid muscle of newly born CHT-/- mice and their CHT+/+ littermates. 
Although comparable evoked and spontaneous responses were initially detected by 
intracellular recordings from muscle fibers in the two genotypes, the ACh release in the 
CHT-/- mice was not sustainable (Fig. 7, 8). After 2–3 h of perfusion, failures 
predominated in the CHT-/- tissue, whereas the amplitude of evoked EPPs remained 
robust and reliable in the CHT+/+ tissue (Fig. 8B, 8D). By 4 h, evoked responses were no 
longer obtained in the CHT-/- muscle fibers, although the resting membrane potential 
remained stable at 52 mV (Fig. 7A). This decline in evoked responses between 1 and 4 h 
of perfusion is paralleled by a decrease in the amplitude and frequency of miniature EPPs 
from a level that is initially indistinguishable from the CHT+/+ control (Fig. 7B). The 
loss of this functional measure of ACh release over time parallels the decline in
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Fig. 7. Electrophysiological characterization of ACh release at CHT–/– NMJs. (A) 
Examples of evoked EPP traces (arrows) from CHT+/+ (left) and CHT–/– (right) 
sternomastoid NMJs 1 or 4 h after birth. Note the absence of evoked EPPs after 4 h in the 
CHT–/– muscles. Stimulation ranged from 1 to 15 V at 1 Hz with 1-ms pulse duration. 
(B) Examples of spontaneous miniature EPPs recorded in the absence of d-tubocurarine 
from CHT+/+ and CHT–/– muscle fibers 1 and 4 h after birth. Data obtained through 
collaborative effort with Joshua Sanes lab. This figure was contributed by Carlos Tapia. 
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Fig. 8. Summary of ACh release defects at CHT–/– NMJs. (A) Evoked-EPP amplitude 
histograms, including failures from +/+ (Left) and –/– (Right) NMJs after 1 and 2–3 hr of 
birth. Failures predominate at the CHT–/– NMJs after 2–3 hr but responses are still 
reliably evoked in the CHT+/+ samples. (B) Graphical summary of the temporal mean 
evoked-EPP amplitude after birth from CHT+/+ and CHT–/– muscles. (C and D) Bar 
graphs showing the mean frequency (C) and amplitude (D) of miniature EPPs from +/+ 
and –/– in the hours after birth. Data were obtained from at least three junctions per 
condition for CHT+/+ and CHT–/– muscles. Data obtained through collaborative effort 
with Joshua Sanes lab. This figure was contributed by Carlos Tapia. 
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movement and progressive cyanosis seen in the CHT-/- pups after birth. Both of these 
findings indicate the presence of an initial limited supply of choline and ACh that 
becomes depleted in the absence of CHT.  
 
Alterations in NMJ Morphology Are Consistent with Diminished ACh Release  
ACh plays a role in utero in the development and maturation of both presynaptic 
and postsynaptic aspects of the NMJ (Sanes and Lichtman, 1999). ChAT-/- mice cannot 
synthesize ACh, and the resulting lack of neurotransmission impairs proper development 
of neuromuscular junctions (Brandon et al., 2003; Misgeld et al., 2002). Therefore, we 
examined several aspects of NMJ morphology to investigate whether the loss of CHT 
function significantly diminished ACh availability during NMJ development. In ChAT-/- 
mice, the loss of ACh synthesis during development resulted in an abnormally broad 
band of nicotinic ACh receptor (nAChR) clusters along intramuscular nerve trunks 
innervating the diaphragm (Brandon et al., 2003; Misgeld et al., 2002). We observed a 
similar phenotype in the CHT-/- mice at E19 (Fig.9 B versus E). To quantify this 
difference, measurements were made at 30- m intervals to assess the maximum diameter 
(perpendicular to axis of band) occupied by nAChR clusters. The mean band diameter 
was 124 ± 22 µm compared with 194 ± 24 µm for CHT+/+ and -/- samples, respectively 
(data not shown). These results represent the average of measurements made from 
multiple fields of Alexa-488-α-bungarotoxin-labeled whole-mount diaphragms from five 
pairs of E19 littermates (640 µm X 640 µm fields, 20 measurements per field, > 3 fields 
per animal, P < 0.005, paired t test). Increases in endplate area were reported in the 
ChAT-/- mutants (Misgeld et al., 2002), and we also observed that individual nAChR 
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Fig. 9. Alterations in nAChR distribution at CHT–/– NMJs. (A) CHT 
immunoreactivity is found in the axons and presynaptic terminals of motor neurons at 
CHT+/+ NMJs of the diaphragm (age = E19; scale bar = 80 µm). (B) Alexa-488--
bungarotoxin labels clusters of postsynaptic nAChR clusters that form a band across the 
diaphragm. (C) The CHT-positive presynaptic terminals overlap the nAChRs on the 
muscle. Alexa-660-phalloidin labeling of actin reveals a regular pattern of muscle fibers. 
(D) CHT immunoreactivity is absent from motor neuron axons and terminals of the 
CHT–/– littermate. (E) The central band of nAChR clusters is wider in the CHT–/– 
diaphragm. (F) The loss of CHT–/– expression does not alter the morphology of the 
muscle fibers. (G) The diameter of the central band is greater at the CHT-/- diaphragm.  
Measurements were made at 30 µm intervals to assess the maximum diameter 
(perpendicular to axis of band) occupied by nAChR clusters.This data represents the 
average of measurements made from multiple fields of alexa-488-BgTx labeled whole 
mount diaphragms from 5 pairs of E19 littermates (640 µm x 640 µm fields, 20 
measurements per field,  >3 fields per animal, p<0.005, paired t test). (H) The area 
occupied by each individual Alexa488-α-bungarotoxin labeled nAChR cluster is also 
increased. This data represents the average area measured from a total of 4621 CHT+/+ 
and 4209 CHT-/- individual alexa488-BgTx labeled nAChR clusters on whole mount 
diaphragm preparations analyzed for 5 pairs of CHT+/+ and -/- littermates (E19, p<0.005, 
paired t test). Figure contributed by Valentina Savchenko. 
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Fig. 10. CHT–/– NMJs are characterized by increased axonal sprouting and 
decreased acetylcholinesterase (AChE) activity. (A) Labeling of motor neuron axons 
for neurofilament immunoreactivity (red) and postsynaptic nAChR clusters by Alexa-
488-α-BgTx (green) shows colocalization at the CHT+/+ diaphragm muscle. (Scale bar = 
80 µm.) Although nAChR clusters colocalize with CHT–/– axons, these axons also 
frequently extend processes beyond the area occupied by nAChR clusters (asterisks). (B) 
Histochemical assays reveal a decrease in AChE activity (revealed by dark precipitate) at 
individual E19 CHT–/– motor neuron terminals compared with CHT+/+ synapses. Figure 
contributed by Valentina Savchenko. 
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clusters are on average larger in the CHT-/- mice compared with wild-type littermates 
(261 ± 17 µm2 versus 202 ± 9 µm2). These data represent the average area measured from 
a total of 4,621 CHT+/+ and 4,209 CHT+/- individual Alexa-488-α-bungarotoxin-labeled 
nAChR clusters on whole-mount diaphragm preparations analyzed for five pairs of CHT-
/- and  +/+ littermates (E19, P < 0.005, paired t test). 
The morphology of the motor neuron axons at the diaphragm was examined by 
labeling for neurofilament immunoreactivity (Fig. 10A). There is a close overlap between 
CHT+/+ motor axons and underlying nAChR clusters, whereas motor axons in the CHT    
mice frequently extend processes beyond areas occupied by nAChRs. Finally, we have 
observed reduced AChE activity at individual synapses in the CHT knockouts relative to 
+/+ littermates (Fig. 10B). These alterations in NMJ morphology parallel, but are perhaps 
less severe than, those reported in the ChAT-knockout mice that are incapable of ACh 
synthesis (Brandon et al. 2003; Misgeld et al. 2002). 
 
Discussion 
Previous work has identified HACU as a major regulator of ACh synthesis 
(Freeman et al., 1979; Guyenet et al., 1973; Haga, 1971). The lethal effects and spectrum 
of cholinergic deficits arising from in vivo HC-3 administration support the physiological 
importance of this mechanism (Schueler, 1955). Nonetheless, work in cultured cells of 
neuroendocrine origin has demonstrated the feasibility of ACh synthesis and vesicular 
release (Bauerfeind et al., 1993) in the absence of detectable CHT expression 
(Apparsundaram et al., 2001b; Ferguson et al., 2003). Studies in neuroblastoma cells 
have also indicated pathways for the release of choline from membrane 
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phosphatidylcholine by phospholipase D (Lee et al., 1993) and low-affinity choline 
uptake mechanisms as sources of choline for ACh synthesis (Richardson et al., 1989). 
Even in neuronal preparations where CHT is present, such as the perfused superior 
cervical ganglia and striatal synaptosome preparations, there are reports of a small 
fraction (20%) of ACh synthesis that is independent of HC-3-sensitive choline uptake 
(Birks and MacIntosh, 1961; Guyenet et al., 1973). 
  
A Lethal Phenotype Arising from Loss of CHT Expression 
At the outset of our current studies, we envisioned several possible major 
phenotypes for CHT-/- mice. Because ACh synthesis and release are absolutely required 
for postnatal survival but are not necessary for viability in utero (Brandon et al., 2003; 
Misgeld et al., 2002), one prediction was that the loss of CHT-mediated presynaptic 
choline uptake might result in neonatal lethality. Alternatively, given the evidence for the 
existence of CHT-independent sources of choline for ACh synthesis, there was a 
possibility that these mechanisms could be up-regulated during development to 
compensate for the lack of CHT. A third possibility was that CHT could have as-yet 
unknown functions during development that could cause embryonic lethality for the 
CHT-/- mice.  
In this study, we show that the CHT-/- mice are born in expected Mendelian ratios 
from the mating of heterozygous parents. However, they fail to survive their first hours of 
life, and their phenotype indicates an impaired ability to sustain the synthesis of adequate 
releasable pools of ACh. Unlike what is observed in the ChAT-/- mice (Brandon et al., 
2003; Misgeld et al., 2002), the normal posture and capacity for movement observed in 
 50
CHT-/- mice at birth indicate the presence of limited stores of ACh produced in the 
absence of CHT. Indeed, our electrophysiological studies of cholinergic 
neurotransmission indicate the presence of a releasable pool of ACh that becomes 
depleted over time unless CHT is available to recapture choline back into the presynaptic 
terminal. Similarly, although we confirmed that CHT is uniquely responsible for both 
HC-3-sensitive HACU and HC-3-sensitive ACh synthesis, we also found evidence for 
HC-3-insensitive ACh synthesis in brain slices from the -/- mice. These latter findings are 
paralleled by observations of ACh synthesis in the caenorhabditis elegans CHO-/-, likely 
supported by LACU mechanisms (Matthies et al., 2006). Overall, our studies confirm a 
unique role for CHT in sustaining cholinergic neurotransmission and indicate that 
although other pathways can supply choline that contributes to ACh synthesis, they are 
not sufficiently robust to compensate for the loss of the CHT-mediated transport activity 
in active cholinergic terminals.  
It seems reasonable to conclude that the phenotypes of the CHT-null mice arise 
from a defect in ACh synthesis at the NMJ, because the only known function of CHT is 
to transport choline into cholinergic neurons, and cholinergic neurotransmission at the 
NMJs of the diaphragm and intercostal muscles controls breathing. Although the 
presence of limited movement and early time point recordings from CHT-/- NMJs 
indicate that some ACh is synthesized and released in the absence of CHT, the CHT-/- 
NMJs exhibit morphological changes that are similar to, but less severe than, the effects 
reported for ChAT-/- mice that completely lack ACh synthesis (Brandon et al., 2003; 
Misgeld et al., 2002). As ChAT and CHT are proposed to act sequentially in ACh 
synthesis and the two knockouts yield similar phenotypes, the most direct explanation is 
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that the diminished cholinergic function at the NMJ of the CHT-/- mice is sufficiently 
severe to reproduce some of the developmental effects previously attributed to total ACh 
loss. Because the CHT-/- mice recapitulate some, but not all, of the phenotypes of ChAT 
-/- animals, we propose that these findings reveal different quantitative thresholds for 
cholinergic signaling, particularly during development. 
 
CHT Sustains Synaptically Releasable Pools of ACh 
The similar total ACh levels in the brains of newborn CHT-/- compared with 
CHT+/+ mice (Fig. 6E) suggest that low levels of neuronal activity and ACh turnover in 
the newborn brain might not place a large demand on ACh synthesized from CHT-
independent supplies of choline. At birth, the CNS cholinergic system is not well 
developed, particularly in the forebrain (Coyle and Yamamura, 1976). However, ACh 
levels greatly exceed expectations based on the relative abundance of ChAT activity at 
this age (Coyle and Yamamura, 1976). It is possible that developing cholinergic neurons 
possess abundant CHT-independent mechanisms for choline uptake to support 
phosphatidylcholine synthesis that could also contribute to ACh production. Indeed, in 
the newborn brain, we measured a sizable pool of HC-3-insensitive ACh synthesis (Fig. 
6F). Nonetheless, both electrophysiological and morphological analysis of CHT-/- NMJs 
demonstrate a defect in the availability of releasable ACh, indicating that the CHT-
dependent choline supply is intimately linked to the generation of synaptically releasable 
pools of ACh. These results are particularly intriguing in light of my findings of 
significantly diminished total ACh levels in the brains of adult CHT+/- mice, which 
appear to be sufficient to sustain baseline ACh releaseable pools and cholinergically-
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mediated behaviors, but likely render the CHT+/- mice vulnerable to direct and sustained 
challenges to cholinergic signaling (Chapter III). 
In summary, the generation and initial characterization of CHT knockout mice 
reported here demonstrates that choline transported by CHT contributes to ACh synthesis 
and is essential for sustaining cholinergic neurotransmission at levels required to support 
life. The recent report of a relatively common, nonsynonymous, single nucleotide 
polymorphism (SNP) in the coding region of human CHT that results in diminished 
choline transport (Okuda et al., 2002), as well as the identification of nonsynonymous 
ChAT SNPs with clinical phenotypes (Maselli et al., 2003; Ohno et al., 2001), predicts 
that variations in absolute levels of cholinergic capacity might be relatively common 
across human populations and set risk thresholds for a variety of disorders or their onset 
severity. In addition to the well recognized deficits in cholinergic function in myasthenic 
syndromes, defects in the capacity for ACh synthesis in the CNS may contribute to 
cognitive dysfunction and dementia and may place demands on the regulatory 
mechanisms revealed by our studies that control CHT function. Further characterization 
of CHT+/- mice (Chapter III), especially with respect to their responses to behavioral or 
pharmacological challenges, should identify distinct functions that are sensitive to 
diminished CHT reserve. 
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CHAPTER III 
 
CHOLINE TRANSPORTER DEFICIENT MICE DISPLAY BASAL CHOLINERGIC 
DEFICITS AND MOTOR ABNORMALITIES IN RESPONSE TO PHYSICAL AND 
PHARMACOLOGICAL CHALLENGE  
 
Introduction 
ACh is a neurotransmitter of key importance in both central and peripheral 
nervous systems. Cholinergic neurotransmission maintains vital biological functions such 
as movement, autonomic regulation, and cognitive processes including attention and 
learning and memory (Kaneko et al., 2000; Misgeld et al., 2002; Perry et al., 1999a; 
Winkler et al., 1995) via both nicotinic (Dani, 2001) and muscarinic (Wess, 2004) 
receptors. CHT activity is believed to be the rate-limiting step for ACh synthesis and 
release, particularly under conditions of elevated cholinergic tone (Birks and Macintosh, 
1957; Jope, 1979a; Simon and Kuhar, 1975). Consistent with this idea, in vitro inhibition 
of CHT by the competitive CHT antagonist HC-3 impairs ACh synthesis and release 
(Guyenet et al., 1973; Maire and Wurtman, 1985; Murrin et al., 1977), whereas in vivo 
pharmacological challenge with sublethal doses of HC-3 impairs learning and memory as 
measured in the Morris water maze and passive avoidance tasks (Boccia et al., 2004; 
Franklin et al., 1986; Hagan et al., 1989). Complete pharmacological blockade of CHT 
(Schueler, 1955) or homozygous deletion of the CHT gene in mice (Chapter II) results in 
death associated with reduced ACh release at central and peripheral cholinergic synapses 
that support respiration, including the neuromuscular junction (NMJ). 
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We identified the murine CHT (mCHT) (Apparsundaram et al., 2001a) with the 
express purpose of establishing novel in vivo models of cholinergic hypofunction derived 
from genetically-determined changes in CHT protein levels. As indicated above, CHT-/- 
newborn mice are apneic and hypoxic, largely immobile, and die within an hour birth 
(Chapter II). In contrast, CHT+/- mice survive, are grossly indistinguishable from 
CHT+/+ mice and exhibit levels of forebrain choline uptake equivalent to that of CHT 
+/+ littermates despite a 50% reduction in CHT protein levels (Ferguson et al., 2004).  
These latter findings are consistent with the existence of efficient, post-translational 
regulation of HACU (Apparsundaram et al., 2005; Ferguson and Blakely, 2004) and/or 
changes in ACh synthesis, release or response. Importantly, CHT +/- mice appear more 
sensitive to HC-3 (Ferguson et al., 2004), suggesting the existence of underlying 
compensatory changes beyond CHT that may be engaged to sustain normal behavior.  
In the experiments described below, I sought to elucidate basal behavioral and 
biochemical phenotypes of CHT+/- mice, and initiate an exploration of altered sensitivity 
in CHT+/- mice to physical and pharmacological challenges. I establish that whereas 
CHT hemizygosity does not result in overt behavioral phenotypes, this condition leads to 
significantly reduced bulk ACh brain levels and renders animals vulnerable to behavioral 
and pharmacological challenges of cholinergically-mediated behaviors. Moreover, I 
identify changes in M1 and M2 muscarinic receptor densities that I hypothesize arise to 
compensate for loss of CHT, but which ultimately alter the dynamic range of cholinergic 
signaling. I discuss my findings in relation to CHT regulation in response to genetic and 
pharmacological challenges and loss-of-function alleles evident in humans. 
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Materials and Methods 
 
Drugs 
Scopolamine hydrochloride (S-1013) and oxotremorine sesquifumarate salt (O-
9126) were obtained from Sigma-Aldrich (St Loius, MO) and dissolved in sterile saline 
(0.9% NaCl).  Both drugs were injected intraperitoneally at a volume of 10 ml/kg. 
 
Mice  
All animal procedures were approved by the Vanderbilt University Institutional 
Animal Care and Use Committee. Mice were housed up to five per cage on a 12-hour 
light/dark cycle (lights on at 0600 am), and behavioral testing was performed during the 
light part of the cycle. Food (Purina Rodent Chow #5001) and water were provided ad 
libitum. All mice were back-crossed at least 7 generations to the C57Bl/6 background 
except in the rotarod, elevated plus maze, and scopolamine-induced locomotion 
experiments, where CHT+/- mice back-crossed for 2 generations were used. In all cases, 
CHT+/+ littermates were used as controls. All behavioral tests were carried out in the 
Murine Neurobehavioral Laboratory of the Center for Molecular Neuroscience, managed 
by Dr. John D. Allison.  Mice naive to behavioral testing were used in each behavioral 
task. Mice were acclimated to the testing location at least 12 hours before the start of 
behavioral testing. 
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Irwin Screen  
 At 12 weeks of age, 7 mice from each genotype were subjected to a modified 
Irwin screen (Irwin, 1968), to assess basic sensory-motor performance. Specifically, the 
following factors were evaluated on a numerical scale of 0-3: gross appearance (presence 
of whiskers, fur, wounds, and body weight); behavior in a novel environment (mice were 
removed from their home cage, placed in a new, clean cage devoid of bedding and 
evaluated for spontaneous activity, tremor, piloerection, tail elevation, urination, and 
defecation); and reflexes (touch escape, reaching reflex, pinna reflex). 
 
Exploratory locomotor activity  
 Locomotion was evaluated in 9- to 12-week-old mice (CHT+/-, n=18; CHT+/+, 
n=19) using a commercially-available activity monitors measuring 27.9 x 27.9 cm (MED 
Associates, Georgia, VT). Each apparatus contained 16 photocells in each horizontal 
direction, as well as 16 photocells elevated 4.0 cm to measure rearing. Mice were placed 
in the monitors for 30 min and allowed to explore freely. Horizontal beam breaks and 
rearing were automatically recorded and represented as distance traveled and vertical 
counts respectively. Data were analyzed in 5-min time bins. 
 
Rotarod 
Motor coordination and balance were measured in 3-month-old mice (CHT+/-, 
n=7; CHT+/+, n=5), using a commercially-available accelerating rotarod apparatus 
(Model 7650, Ugo Basile, Napoli, Italy). Mice were placed on the rotating cylinder (3 cm 
in diameter) and confined to a section approximately 6.0 cm long by grey plastic dividers. 
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The rotational speed of the cylinder was increased from 5 to 40 r.p.m. over a 5-min 
period. Latency at which mice fell off the rotating cylinder was measured.  Each mouse 
was given 3 trials per day over a period of 3 days. 
 
Elevated plus maze   
Anxiety was evaluated using the elevated plus maze. The home-made plus maze 
consisted of four arms, approximately 10 x 30 cm, connected in a plus configuration and 
elevated approximately 40 cm above the floor. Two of the arms had walls, approximately 
15 cm high (“closed arms”), and two walls had no arms (“open arms”).  Mice were 
placed gently in the center of the four arms at the beginning of the session. The number 
of entries onto the open arms, and amount of time spent in open arms were recorded. 
 
Light-dark exploration   
Anxiety responses were also assessed in 2- to 3-month-old mice (n=8 per 
genotype), using the activity monitors (MED Associates, Georgia, VT). Half of the 
chamber was made opaque with a black acrylic insert, while the other half remained 
transparent.  Photocells recorded the movement of the mice between compartments.  
Mice were placed individually into the dark compartment at the beginning of the session. 
Total time spent in the dark versus light compartments were recorded. Each mouse was 
given one 5-minute session. 
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Morris water maze  
Spatial learning and memory were evaluated in CHT+/- (n=11) and CHT+/+ 
(n=12) mice using the hidden-platform water-maze paradigm. The water maze pool was 
92-cm in diameter and filled with water made opaque with non-toxic tempura paint.  An 
acrylic platform (10x10 cm) was submerged approximately 0.5 cm below the surface of 
the water to allow relief from swimming. The mice were given six spaced trials per day. 
The hidden platform remained in a fixed location throughout the experiment, but starting 
positions were different on each trial.  Each trial continued for a maximum of 60 sec or 
until the mouse reached the platform, whichever occurred first. If a mouse did not reach 
the platform in 60 sec it was captured by the experimenter and placed gently on the 
platform for 15 sec. Sessions were captured by an overhead camera and analyzed in real 
time using an NIH Image macro on a Macintosh computer. Parameters measured 
included latency (time to reach platform), swimming velocity, and path length. Data were 
analyzed immediately following each set of trials, and once each group of mice reached 
criterion or 8 sec average latency, they were given a probe test 2 hours after their last 
training session. Both genotypes reached criterion on the same day, and therefore all mice 
received the same number of trials.  
In the probe trial, the platform was removed, and mice were allowed 60 sec to 
explore the water maze. The amount of time spent in each quadrant of the pool and 
platform location crossings were measured for the 60-sec probe trial. A second probe trial 
was performed 48 hours after the initial probe trial. Following this, mice were re-trained 
using a new platform location. Platform location was constant across days, and each 
mouse was ran for 6 spaced trials (6 different starting locations) each day until target 
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latency to reach the platform (8 sec average for each genotype) was reached. Probe trials 
were ran 2 hours and 48 hours after the last reverse platform training trial. 
 
Treadmill  
Eight- to 10-week-old mice (n=11 per genotype) were run on a motorized, 6-lane 
treadmill (Columbus Instruments, Columbus, OH) equipped with an adjustable-speed belt 
(6-100 M/min), and an electric shock grid at one end. On day 1 (training) the mice were 
exposed to the treadmill without running or shock for 10 min. They were then exposed to 
gradually-increasing speeds (10 m/min maximum) for 15-30 min in the presence of 
electric shock (2 mA, 4 min-1 frequency) activated by physical contact with the shock 
grid. This trial was used purely for training purposes and to familiarize the mice with the 
apparatus. On day 2 (gradual increase in speed) the mice were started at 10 m/min and 
the speed was increased by 1.5 m/min every 2 min. The maximal speed achieved by each 
mouse and the maximal time a mouse could keep running were recorded and interpreted 
as measures of motor fatigue. Exhaustion was defined as resting on the electric grid for 
more than 15 sec/min or falling back onto the grid more than 15 times/min. On day 3 
(constant speed) the initial running speed was 6 m/min, and was increased every 30 sec 
by 2 m/min until a speed of 17 m/min was reached after 2.5 min. At this point the speed 
was maintained at 17 m/min and the mice were run until exhaustion. To exclude the 
possibility that the phenotype was due to learning difficulties, the mice were tested in the 
same paradigm on 2 additional consecutive days, and similar results were obtained. As a 
control for pain sensitivity, I tested a separate group of experimentally-naive littermates 
(n=7 per genotype). I exposed the individual mice to shock of increasing current 
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amplitude, with rest periods between shocks of varying amplitudes, and recorded the 
current amplitudes at which the mouse first jumped and/or vocalized, as a readout of 
sensitivity to shock.  
 
Scopolamine-induced locomotor activity 
On drug test days the mice were acclimated to the activity monitors (MED 
Associates, Georgia, VT) for 1 hour, removed and injected i.p. with vehicle or 
scopolamine, and returned to the activity monitors for 2 hours for activity measurements.  
Naïve mice were used for each drug concentration. N=8, n=12, and n=5 mice from each 
genotype were used for the 1mg/kg, 0.5 mg/kg, and 0.1 mg/kg doses respectively.   
 
Oxotremorine-induced tremor 
Mice were taken from their home cages and placed in new, individual (one 
mouse/cage) transparent cages devoid of bedding, and allowed to acclimate for 15 
minutes. Each mouse was injected i.p. with vehicle or oxotremorine, and returned to the 
cage for observation. Naïve mice were used for each drug concentration, and the observer 
was blind to the genotypes. N=5 mice from each genotype were used for the 0.125 mg/kg 
and 0.031 mg/kg doses, and n=17 mice from each genotype were used for the 0.062 
mg/kg dose.  Tremor was scored every 5 minutes on a scale of 0-2 (0 = no tremor, 1 = 
head and body tremor, 2 = continuous tremor whole body tremor). The data were 
expressed as percent of the maximal possible tremor  (for example a score of 1 was 
represented as (1 (actual score)/2 (maximum possible score)*100=%tremor) (Li et al., 
2003).  
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Synaptosomal Biotinylation.  
I evaluated plasma membrane CHT protein density in crude synaptosomes using 
the membrane-impermeant biotinylating reagent, sulfosuccinimidobiotin (NHS-biotin) 
(Pierce Chemical, Rockford, IL). Crude synaptosomes (150 µg of protein/reaction) were 
incubated with NHS-biotin (3 mg/ml) for 45 min at 4°C, after which ice-cold 1M Tris 
buffer (pH 7.8) was added, and the reactions were spun at 11k rpm for 5 min at 4°C. The 
pellet was resuspended in KRH/Tris buffer, spun down again, and lysed with 500 µl of 
radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 
mM EDTA, 0.1% SDS, 1% Triton, and 1% sodium deoxycholate) supplemented with 
protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml aprotinin, and 250 µM 
phenylmethylsulfonyl fluoride). The extracts were incubated with streptavidin beads 
(Pierce Chemical, Rockford, IL) in the same buffer for 1 h at 4°C. Following the 
incubation, the biotinylated fractions bound to the beads were separated by 
centrifugation, washed in RIPA lysis buffer three times, and eluted by washing in 
Laemmli buffer (62.5 mM Tris, pH 6.8, 20% glycerol, 2% SDS, and 5% bromphenol 
blue, supplemented with 5% -mercaptoethanol) for 30 min at room temperature. Aliqots 
of total extract (10% of crude synaptosomal preps) and bead eluents were used in SDS-
PAGE for protein separation as described in Immunoblotting methods section (Chapter 
II). Calnexin immunoblotting was used as a negative control to monitor biotinylation of 
intracellular proteins by membrane-impermeant NHS biotin, whereas transferin receptor 
immnoblotting was used as a positive control for plasma membrane protein biotinylation. 
CHT protein band densities were normalized to transferin receptor band densities. 
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ACh levels, ChAT and AChE Activity 
ACh levels in brain tissue were quantified by previously described high 
performance liquid chromatography (HPLC) electrochemical detection methods  
(CHT+/-, n=7; CHT+/+, n=7) (Vanderbilt Neurochemistry Core Resource) (Damsma et 
al., 1985). Briefly, brain tissue was microwaved for acetylcholinesterase (Bertrand et al., 
1994), followed by homogenization in acetonitrile, lipid removal with heptane, and 
vacuum drying. Activity of ChAT was measured by the synthesis of [14C]ACh from 
[acetyl-1-14C]acetyl-CoA and choline (CHT+/-, n=4; CHT+/+, n=4) (Frick et al., 2002). 
AChE activity was determined by colorimetric measurements following the method of 
Ellman (CHT+/-, n=5; CHT+/+, n=5) (Ellman et al., 1961). 
  
Immunoblot analysis of mAChR expression   
Freshly dissected brain tissue (n=4 mice per genotype) was frozen in tubes on dry 
ice and stored at -80°C. As needed, tubes were removed from -80°C and placed on ice. 
Protease inhibitor (Sigma, St. Louis, MO, #2714) was dissolved in 10 mM Tris, 1 mM 
EDTA, pH 7.5, and 500 ul was added to each tube. The tissue was homogenized with a 
Brinkman Polytron PT3000 using a PT-DA 3007/2 tip at 20k rpm for 10 seconds and the 
tip was rinsed with dH2O between each sample. After determining and adjusting protein 
concentration, the homogenate was diluted with sample buffer to yield 1% sodium 
dodecyl sulfate (SDS), 31.25 mM TRIS pH 6.8, 5% glycerol, 200mM 2-
mercaptoethanol.  The samples were then resolved on a 10% gel by SDS-polyacrylamide 
gel electrophoresis (PAGE), transferred to polyvinylidine difluoride membranes and 
subjected to immunoblot analyses with M1 and M2 polyclonal antibodies (Li et al., 2003; 
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Volpicelli-Daley et al., 2003b), as well as an EF1a monoclonal antibody for loading 
control, using an Odyssey imager (Li-Cor, Lincoln, NE). Blot densitometry was 
performed using ImageJ software (Wayne Rasband, NIH) and the muscarinic receptor 
band densities were normalized to the EF1a band densities (Volpicelli-Daley et al., 
2003b). 
 
Statistical analyses 
 Two-way repeated measures ANOVA and two-tailed, unpaired Student’s t tests 
were used to analyze the data. The specific statistical analyses used are noted in the text 
and legends with respect to individual test design. 
 
Results 
 
CHT+/- mice exhibit wild-type levels of overall locomotor activity, but altered patterns 
of movement in the open field chamber paradigm 
Basal exploratory locomotor activity was evaluated in CHT+/- mice and CHT+/+ 
siblings in the open field activity monitors. CHT+/- mice consistently traveled shorter 
distances during their first 30 minute exposure to the open field chambers (CHT+/-, 3081 
± 171.8 cm; CHT+/+, 3658 ± 217.7 cm) (Fig 11A). This difference was statistically 
significant (F(1, 180) = 4.33; P < .05). In preliminary studies, we also observed diminished 
motor activity upon initial, but not continued exposure to a running wheel setup in the 
home cage (data not shown), suggesting a novelty effect may be responsible for the 
CHT+/- hypolocomotive phenotype. Intriguingly, vertical movement was higher in the 
CHT+/- mice (711.4 ± 79.0 counts) compared to their CHT+/+ siblings (463.5 ± 90.3  
 64
 
 
 
 
 
Figure 11. CHT+/- mice display altered basal locomotion in the open field paradigm. 
CHT+/- mice display reduced horizontal locomotion (A), and increased vertical activity 
(B) in the novel open field environment compared to CHT+/+ littermates. When 
horizontal activity is corrected for the additional time spent rearing, activity levels are not 
significantly different between the genotypes (C). Filled triangles, CHT+/- (n=18); open 
squares, CHT+/+ (n=19).  Mean (±SEM) values are indicated (*p<0.05).  
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counts) (F(1, 175) = 5.04; P < 0.05) (Fig. 11B).   The inverse relationship between 
ambulatory and rearing counts suggests that lower levels of horizontal activity by the 
CHT+/- mice may be due to increased vertical activity, possibly due to increased 
exploratory drive, rather than impairments in sensory-motor ability. Indeed, when time 
spent in vertical motion was eliminated from recordings, CHT+/- and CHT+/+ mice 
showed equivalent distance traveled (Fig. 11C).  
 
Basal sensory-motor performance is intact in CHT+/- mice 
A modified Irwin screen (Irwin, 1968) failed to reveal any difference in basal 
sensory-motor phenotypes between genotypes (data not shown). In addition, the mice 
were tested on a rotarod test. Both genotypes learned the task at the same rate and 
demonstrated equivalent performance, as indicated by increases in similar average 
latencies before falling off the accelerating rod over a period of 3 consecutive trial days 
(Day 1 latencies: CHT+/-, 66.4 ± 13.4 sec vs CHT+/+, 63.2 ± 22.7 sec; Day 2 latencies: 
CHT+/-, 188.6 ± 27.1 sec vs CHT+/+, 169.1 ± 39.0 sec; Day 3 latencies: CHT+/-, 245.6 
± 26.0 sec vs CHT+/+, 194.5 ± 35.0 sec (Fig. 12A). There was also no significant 
difference in the amount of time CHT+/+ and CHT+/- littermates were able to hold onto 
an inverted screen (data not shown). These results suggest that a single functional CHT 
allele is sufficient to support overall motor balance and coordination as well as muscle 
strength. 
 
CHT+/- mice do not show elevated anxiety 
 One possible explanation for the changes in vertical activity observed in the open
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Figure 12. Basal sensory-motor and anxiety behaviors are normal in the CHT+/- 
mice. Motor coordination, balance, and learning are similar between CHT+/- (n=7) and 
CHT+/+ (n=5) littermates in the rotarod paradigm (average latencies of 3 trials/day) (A). 
Anxiety levels are similar between CHT+/- mice and CHT+/+ littermates as indicated by 
same amount of time spent in open versus closed arms in the elevated plus maze 
(n=5/genotype) (B), in center vs periphery in open field/novel environment paradigm 
(CHT+/-, n=18; CHT+/+, n=19) (C), and in light vs dark section of the light/dark 
paradigm (CHT+/-, n=6; CHT+/+, n=8) (D). Mean (±SEM) values are indicated.  
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field paradigm is elevation in anxiety.  To test this hypothesis, the distance traveled in the 
center versus the periphery of the open field was evaluated in the same open field trials 
used to quantify locomotor movement.  I found no significant genotype difference in the 
ratio between distance traveled in the center versus periphery (arbitrary units: CHT+/-, 
2.92 ± 0.41; CHT+/+, 2.53 ± 0.34) (Fig. 12C). For an additional evaluation of anxiety, a 
separate, naïve group of mice was given a 5-min trial in the light/dark paradigm. Again, 
there was no significant difference between genotypes in the amount of time they spent in 
the light (CHT+/-, 112.8 ± 23.4 sec; CHT+/+, 99.2 ± 9.0 sec), versus the dark (CHT+/-, 
186.2 ± 23.4 sec; CHT+/+, 199.8 ± 9.0 sec) part of the field and, as expected, both 
genotypes spent more time in the dark part of the field (Fig. 12D).  In a final evaluation 
of anxiety, mice were tested on the elevated plus maze. Consistent with other anxiety 
measures noted above, the percent time spent in open arms (CHT+/-, 17.4 ± 5.7%; 
CHT+/+, 18.5 ± 2.7%) versus closed arms (Fig. 12B) (CHT+/-, 69.2 ± 5.9%; CHT+/+, 
56.1 ± 8.0 %), and percent entries into open (CHT+/-, 25.3 ± 6.7%; CHT+/+, 31.5 ± 
7.6%) versus closed (CHT+/-, 58.7 ± 7.6%; CHT+/+, 60.5 ± 10.8%) arms were not 
different between the genotypes.  
 
CHT+/- mice display normal performance in the Morris water maze 
With findings of normal baseline sensory-motor performance in the CHT+/- mice, 
I next evaluated CHT genotype effects on spatial learning and memory using the Morris 
water maze (Winkler et al., 1995). CHT+/- mice did not differ from CHT+/+ littermates 
in any aspect of the task. Both genotypes learned the Morris water maze task equally well 
as indicated by similar latencies to reach the platform (Fig. 13A) (F(1,147) = 0.01; P = 0.31) 
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and decreasing latencies over 8 days of training (F(7,147) = 31.02; P < 0.0001).  CHT+/- 
mice were also unimpaired in acquisition of a novel platform location (F(1,60) = 0.09; P = 
0.91) (Fig. 13B) and had similar swim speeds (data not shown). On the probe trial, both 
CHT+/- and CHT+/+ mice spent significantly greater periods of time in the target 
quadrant (CHT+/-, 44.5 ± 1.3% of total time (F(3,30) = 37.19; P < 0.0001); CHT+/+, 41.3 
± 1.8% of total time (F(3,33) = 13.59; P < 0.0001) (Fig. 13C), indicating intact memory for 
the platform location.  Similarly, mice of both genotypes were more likely to swim over 
the former platform location, compared to equivalent locations in the other three 
quadrants (CHT+/-, 3.3 ± 0.9 and CHT+/+, 2.2 ± 0.5 number of crossings over former 
platform location) (Fig. 13D).  No differences in any of the above parameters were 
observed upon repeating the probe trial 48 hours after the last training session (data not 
shown) or upon reversing the platform location and repeating the learning and probe 
trials. To evaluate the effects of aging on spatial learning, a group of naïve 1.5-year-old 
mice of identical genetic background were tested in the same water maze paradigm using 
the same test parameters, with results similar to those obtained with younger animals 
(data not shown). 
 
CHT+/- Mice Are Hypersensitive to the Effects of HC-3 
The wild type behavior by the CHT+/- mice in the above assays leads to the 
question – while CHT hemizygosity appears to be sufficient to support baseline 
physiology, do challenges directed at CHT function compromise CHT+/- performance? 
Intraperitoneal injection of the CHT inhibitor, HC-3, results in hypocholinergic function 
and death (Schueler, 1955). Furthermore, inhibition of choline uptake into synaptosomes
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Figure 13. CHT+/- baseline spatial learning and memory performance are normal 
in Morris water maze paradigm.  3-month-old CHT+/- (n=11) and CHT+/+ (n=12) 
mice were run in the hidden platform version of the Morris water maze.  The CHT+/- 
mice did not differ on latency to reach the platform during learning trials with original 
(A) and reversed (B) platform locations.  Both genotypes spent similar amounts of time 
in the target quadrant on probe trials on the last day of training (C) as well as a delayed 
probe trial (48 hours later, data not shown), and did not differ in number of platform 
location crossings (D). T = target (platform), O=opposite, R=right, L=left quadrant.  
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with HC-3 evokes a subsequent increase in choline uptake after the inhibitor is washed 
away, suggesting that the CHT reserve can be recruited by inhibiting choline uptake 
(Rylett et al., 1993). If the CHT+/- mice have already functionally compensated for 
diminished CHT levels, perhaps in part by depleting their vesicular reserves, then they 
might exhibit greater sensitivity to the lethal in vivo effects of HC-3. Therefore, I next 
tested the HC-3 sensitivity of adult male CHT+/- mice (Fig. 14D). The behavior of the 
mice after HC-3 administration was similar to that in the original reports of the toxicity of 
this drug and included labored breathing and convulsions (Schueler, 1955). At a HC-3 
dose of 46 µg/kg, wild-type mice displayed labored breathing but then recovered normal 
function with 100% survival (n = 9), whereas the majority (60%) of the CHT+/- mice did 
not survive. Likewise, at a dose of 175 µg/kg, all CHT+/- mice died (n = 6) but 50% of 
wild-type mice still survived (n = 6). At the highest dose examined (655 µg/kg) I 
observed no survival for the CHT+/- animals (n = 9), whereas only 1 of 6 CHT+/+ mice 
survived. In comparing the animals of the two genotypes that did not survive the 655 
µg/kg HC-3 challenge, the time required for death to occur was significantly less for the 
CHT+/- mice compared with their +/+ littermates (Fig. 14B) (7.6 ± 0.8 min versus 12 ± 
1.2 min, P < 0.05, Student’s t test). 
 
Physical challenge unmasks a locomotor phenotype in the CHT+/-s  
 The lack of impairment in the behavioral tasks described previously suggests that 
cholinergically-supported motor function and spatial learning and memory are normal in 
the CHT+/- mice under standard measurement conditions. However, the HC-3 lethality 
studies clearly uncover altered CHT+/- susceptibility to challenge directed at 
 71
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. CHT+/- mice are hypersensitive to the effects of HC-3. (A) CHT+/- mice 
are more sensitive to the lethal effects of HC-3 (i.p. injection) than their +/+ littermates: 
100% (n = 9), 50% (n = 6), and 17% (n = 6) survival were observed in CHT+/+ mice 
with increasing HC-3 doses, whereas the same HC-3 doses resulted in lower survival 
rates, 40% (n = 10), 0% (n = 6), and 0% (n = 9) in CHT+/- littermates. (B) At the highest 
HC-3 dose (655 µg/kg) the mean survival time was significantly decreased in the CHT+/- 
mice  (7.6+/-0.8 versus 12+/-1.2 minutes, *p<0.05, t test). 
A 
B 
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cholinergically-supported behaviors. Therefore, I next focused on locomotor performance 
of the CHT+/- animals, and used the treadmill paradigm in order to introduce graded 
physical demands. My hypothesis was that under conditions of sustained physical 
challenge – such as continuously increasing treadmill speed (gradual challenge) and/or 
sustained high speed (acute challenge) – motor performance would be interrupted sooner 
in the CHT+/- mice compared to their CHT+/+ littermates. Quantitative predictions were 
that the CHT+/- mice would be unable to reach treadmill speeds as high as those attained 
by CHT+/+ littermates, and that at a constant treadmill speed the CHT+/- mice would 
fatigue sooner than the CHT+/+ littermates.  Both predictions were confirmed 
experimentally: whereas both genotypes were able to sustain activity on the treadmill 
initially, the average time spent running in the gradual acceleration version of the task 
was significantly lower in the CHT+/- mice (772 ± 60.6 sec) compared to CHT+/+ mice 
(1089 ± 55.8 sec) (t(12) = 3.85, P < 0.001) (Fig. 15A). In addition, 18% of CHT+/+’s 
reached maximal speeds of 25 m/min, while none of the CHT+/-’s exceeded 22 m/min, 
and only 9% CHT+/- mice reached 22 m/min, versus 45% of CHT+/+’s (Fig. 15B).  
In the acute challenge paradigm, the average time spent running was again 
significantly lower in the CHT+/- mice (1169 ± 139.5 sec) as compared to CHT+/+ 
littermates (1743 ± 146.3 sec) (t(12) = 2.84, P < 0.01) (Fig. 15C). Whereas both genotypes 
performed similarly initially (100% of both genotypes remained on the treadmill at 10 
min), only 45.4% of CHT+/- mice, compared to 81.8% of CHT+/+ mice remained on the 
treadmill by 20 min, only 18.2% of CHT+/- mice but 72.7% of CHT+/+ littermates 
remained by 30 min, and 0% of CHT+/- mice versus 64.6% of CHT+/+ animals remained 
longer than 35 min (Fig. 15B). It is unlikely that the differences were due to lack of
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Figure 15. Physical challenge unmasks a locomotor phenotype in the CHT+/- mice. 
CHT+/- mice (n=11) remained on the treadmill for significantly shorter periods of time in 
both gradual (A) and acute (C) challenge versions of the treadmill paradigm compared to 
CHT+/+ littermates (n=11). In addition, while both genotypes performed similarly 
initially, CHT+/- mice displayed motor fatigue sooner (D), and none of the CHT+/- mice 
reached the maximal speed reached by the CHT+/+ littermates (B). Mean (±SEM) values 
are indicated (*p<0.01,***p<0.001).  
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sensory feedback in the mice, as all mice vocalized and/or jumped when exposed to the 
electric grid, and immediately resumed running either voluntarily or in response to gentle 
prodding, unless they were completely exhausted. In addition, a separate experimentally-
naïve group of mice was tested for responses to increasing shock amplitudes, and no 
significant differences in shock sensitivity were evident between genotypes: CHT+/- 
mice first vocalized at 0.33 ± 0.02 mA of current, while CHT+/+ mice vocalized at 0.35 ± 
0.04 mA of current. 
 
Locomotor phenotype in CHT+/- mice is induced by muscarinic challenge 
 To complement studies of physical stress on cholinergic systems, I investigated 
pharmacological challenges known to impact ACh signaling and ensuing locomotor 
performance. Challenge with muscarinic antagonists has a well-known stimulatory effect 
on locomotor activity, mediated by increased ACh release (Gerber et al., 2001; Gomeza 
et al., 1999b; Miyakawa et al., 2001; Sipos et al., 1999). I constructed a dose-response 
profile for CHT+/- mice and CHT+/+ littermates, using open field locomotor behavior as 
a measure of motor activity (Fig. 16). In both genotypes, locomotion was not affected or 
increased equally at low (0.1 mg/kg) (F(1,72) = 1.26, P = 0.29) (Fig. 16A) and high (1 
g/kg) (F(1,169) = 0.26, P = 0.62) (Fig. 16C) doses of scopolamine, respectively.  
 However, at an intermediate dose (0.5 mg/kg), the CHT+/- mice were 
significantly less active than their CHT+/+ littermates (Fig. 16B) (F(1,308) = 4.94, P < .05) 
(Fig. 16D). The difference in sensitivity to scopolamine was evident in measurements of 
distance traveled only, as both genotypes displayed equal increases in vertical counts 
following scopolamine injection (data not shown). 
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Figure 16. Locomotor phenotype in CHT+/- mice is induced by muscarinic 
challenge. In both genotypes (CHT+/-, n=11; CHT+/+, n=12), locomotion was not 
affected or increased equally at low (0.1 mg/kg) (A) and high (1 mg/kg) (C) doses of 
scopolamine respectively. However, at an intermediate dose (0.5 mg/kg) (B), the CHT+/- 
mice were significantly less active than the CHT+/+ littermates, showing a decreased 
sensitivity to the muscarinic antagonist scopolamine (D). Arrow = point of drug 
administration (*p<0.05). 
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 In contrast to their hyposensitivity to scopolamine challenge, the CHT+/- mice 
displayed a dose-dependent increased sensitivity to the muscarinic agonist oxotremorine. 
Similar to the effects of scopolamine, oxotremorine induced dose-dependent increases in 
tremor response of the CHT+/- compared to CHT+/+ littermates. There was no difference 
between the genotypes at low (0.031 mg/kg) and high (0.125 mg/kg) doses of 
oxotremorine. However, 15 min after injection of an intermediate dose (0.062 mg/kg), the 
CHT+/- mice displayed a higher degree of tremor (29.4 ± 6.1%) compared to the 
CHT+/+’s (11.8 ± 5.3%) (t(31) = 2.17, P < 0.05 by non-parametric unpaired t-test). This 
hypersensitivity trend persisted as long as 25 min post-injection (CHT+/-, 41.2 ± 4.8%; 
CHT+/+, 20.6 ± 6.1%; t(30) = 2.65, P < 0.01 by non-parametric unpaired t-test).  
 
Posttranslational Compensation Maintains Cholinergic Function in CHT+/- Mice  
Having investigated basal and challenge-induced behavioral phenotypes, I next 
turned to biochemical characterization of the CHT+/- mice. As evident from the 
successful generation of CHT-/- mice, heterozygotes are viable and fertile, yet they 
exhibit only half the wild-type levels of CHT protein (Fig. 18A). Interestingly, although 
CHT protein levels are diminished, the rate of choline uptake into synaptosomes from 
CHT+/- mice was equivalent to that of their +/+ littermates (Fig. 17A), and had an 
identical dose-response profile to HC-3 inhibition as wild type (Fig. 17B). Analysis of 
saturation kinetics revealed no difference in either the Kd or the Vmax of whole-brain 
synaptosomal [3H]choline transport. Furthermore, in additional choline uptake 
experiments in whole-brain synaptosome preparations that used a single concentration of 
[3H]choline (50 or 100 nM) no significant difference (t test, P > 0.05) was detected 
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Figure 17. Functional compensation of CHT function in adult CHT+/- mice. (A) In 
whole brain synaptosome preparations, CHT+/- levels of HC-3-sensitive choline uptake 
are indistinguishable from wildtype levels. This example of saturation kinetics analysis 
demonstrates no significant difference in either Kd or Vmax between CHT+/+ mice and 
their +/- littermates. From three independent experiments (+/+ and +/- littermates aged 7-
37 weeks old) performed in triplicate the Kd values were 2.9+/-0.3 µM and 3.3+/-0.3 µM 
and the Vmax values were 4.2+/-1.2 and 3.9+/-1.2 pmol/mg protein/minute for CHT+/+ 
and +/- respectively (mean+/-SEM). (B) In parallel with the compensations in HC-3-
sensitive choline uptake, IC-50 values of HC-3 inhibition of HACU were not different 
between genotypes (CHT+/+, IC50=5.1x10-9; CHT+/-, IC50=5.0x10-9 ) (uptake was 
performed in forebrain synaptosomes,in the presence of 50 nM 3H choline, and 0-100 
uM HC-3; n=3, mean+/-SEM of assays performed in triplicate). Shawn Ferguson 
contributed to this figure. 
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between CHT+/- and +/+ littermates (CHT+/- = 107 ± 11% of wild-type choline uptake, 
mean   SEM, n = 8 pairs of male littermates, mean age = 12 weeks, range 5–37 weeks). 
Consistent with these findings, choline clearance rates monitored with ceramic-based 
choline-sensitive electrodes in the striatum of CHT+/- mice were also indistinguishable 
from clearance dynamics observed in the striatum of +/+ littermates (Subbu 
Apparsundaram, personal communication).  
Notably, when we measured [3H]HC-3 binding to whole-brain membrane 
fractions, binding levels exceeded the 50% predicted by genotype and total CHT protein 
levels and were not significantly different (t test, P > 0.05) from the wild-type littermates 
(Fig. 18B). However, synaptosomal biotinylation and immunoblotting revealed CHT 
plasma membrane levels in CHT+/- synaptosomes close to half of those in CHT+/+ 
preparations (Fig. 18A, 18C) (t test, P < 0.05). The complete compensation of CHT 
activity in synaptosomes from CHT+/- mice with only half total and plasma membrane 
wildtype CHT protein expression suggests that cholinergic neurons can use 
posttranslational regulatory mechanisms, such as catalytic activation, to control the rate 
of presynaptic choline uptake.  
 
ACh levels are significantly diminished and muscarinic receptor expression selectively 
altered in the CHT+/- brain 
Do compensatory mechanisms in the CHT+/- brain involve additional participants 
in cholinergic signaling, such as enzymes or receptors present at the cholinergic synapse? 
I based my inquiries into this question on the pharmacological phenotypes of the CHT+/- 
mice described above. The altered CHT+/- sensitivity to muscarinic agents could be due 
to genotype-dependent alterations in ACh levels, as dictated by compensatory changes in 
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Figure 18. Post-translational CHT regulation in adult CHT+/- brain. (A) CHT 
protein levels are diminished in whole brain extracts of CHT+/- mice compared to 
samples from +/+ littermates while TRF protein levels are unchanged. (B) [3H]-HC-3 
binding to whole brain membrane preparations was not different between CHT+/+ and 
+/- mice. (C) However, synaptosomal biotinylation revealed significantly lower CHT 
protein density at the CHT+/- plasma membrane (63.1+/-4.8% of +/+), while 
biotinylation signal for the positive control plasma membrane protein transferin did not 
differ between genotypes (A); (n=3, mean+/-SEM of assays performed in triplicate); 
TRF, transferin receptor. Shawn Ferguson cotrnibuted to this figure. 
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biosynthetic/catabolic pathways, or could arise from changes in muscarinic receptor 
expression. I examined the former possibility by evaluating bulk ACh and choline levels, 
as well as ChAT and AChE activities in various brain regions. Bulk ACh levels were 
significantly lower (Fig. 19A) in the CHT+/- cortex (CHT+/-, 6.9 ± 1.5; CHT+/+, 15.8 ± 
2.3 nmol/g wet tissue), hippocampus (CHT+/-, 9.0 ± 2.1; CHT+/+, 20.6 ± 2.2 nmol/g), 
and striatum (CHT+/-, 24.1 ± 5.2; CHT+/+, 61.7 ± 8.0 nmol/g) (F(1, 3931) = 16.28, P < 
0.001). Conversely, bulk choline levels were significantly elevated (Fig. 19B) in the 
CHT+/- cortex (CHT+/-, 53.0 ± 6.2; CHT+/+, 31.0 ± 2.6 nmol/g wet tissue), 
hippocampus (CHT+/-, 37.7 ± 5.0; CHT+/+, 27.6 ± 1.4 nmol/g), and striatum (CHT+/-, 
66.9 ± 5.0; CHT+/+, 46.9 ± 4.9 nmol/g) (F(1, 3151) = 10.74, P < 0.01).  There were no 
significant differences in ChAT activity (cortex, CHT+/-, 52.0 ± 1.9; CHT+/+, 51.3 ± 
8.3; hippocampus, CHT+/-, 60.2 ± 4.6; CHT+/+, 61.8 ± 4.4; striatum, CHT+/-, 123.8 ± 
27.8; CHT+/+, 130.2 ± 9.9 nmol/hr/mg protein) (F(1, 470) = 0.05, P = 0.83) or AChE 
activity (cortex, CHT+/-, 51.8 ± 4.3; CHT+/+, 51.5 ± 4.3; hippocampus, CHT+/-, 54.7 ± 
13.9; CHT+/+, 44.8 ± 7.4; striatum, CHT+/-, 288.0 ± 51.0; CHT+/+, 288.2 ± 16.2 
nmol/hr/mg protein; (F(1, 126) = 0.13, P = 0.72).  
To test whether alterations were evident in central muscarinic receptors, we 
performed Western blotting for the M1 and M2 receptor on brain homogenates from 
CHT+/- and CHT+/+ littermates, using blot densitometry to quantify receptor expression 
in the cortex, hippocampus, and striatum regions. I focused on these receptors as M2 
receptors represent the predominant presynaptic subtype in cortex and hippocampus, but 
are also expressed in striatum (Rouse et al., 1997) and M1 receptors are widely 
distributed and participate in both motor and cognitive circuits in the cortex,
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Figure 19. ACh and choline levels are significantly altered in the CHT+/- brain. 
Tissue ACh levels measured by HPLC are significantly lower in CHT+/- cortex, 
hippocampus, and striatum (A), whereas choline levels are elevated in the same regions 
(B) (CHT+/-, n=7; CHT+/+, n=7) (*p<0.05, **p<0.01). 
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hippocampus and striatum (Alcantara et al., 2001). 
I found M1 expression to be 25.4% lower in the striatum, 31.3% lower in the 
hippocampus, and 20.8% higher in the cortex of CHT+/- mice compared to CHT+/+ 
littermates (Fig. 20A). This difference reached statistical significance in the striatum (t(6) 
= 3.05; P < 0.05).  M2 receptor expression was 47.7% lower in the striatum, 34.9% lower 
in the cortex, and essentially unchanged in the hippocampi of CHT+/- mice compared to 
CHT+/+ littermates (Fig. 20B). The decreases in M2 expression reached statistical 
significance in both striatum (t(6) = 2.81; P <  .05) and cortex (t(6) = 2.91; P < 0.05).  
 
Discussion 
 Mouse models featuring genetically-established cholinergic deficits have 
provided new evidence for a dynamic role of CHT as a critical modulator of cholinergic 
neurotransmission. For example, CHT protein expression increases in response to 
decreased turnover of ACh in AChE knockout mice (Volpicelli-Daley et al., 2003b). 
Conversely, CHT density and function are upregulated in hypocholinergic states, 
produced by overexpression of AChE in transgenic mice (Beeri et al., 1997). Finally, 
upregulation of CHT protein and function sustains wild type levels of AChE activity, as 
well as bulk ACh content and depolarization-evoked ACh release in ChAT heterozygote 
mice (Brandon et al., 2004). In this context, I hypothesized that partial loss of CHT might 
represent a unique model of cholinergic hypofunction, one where phenotypes might 
emerge upon behavioral/ pharmacological challenges. In support of this idea, I previously 
reported an increase in the sensitivity to the lethal effects of HC-3 in CHT+/- mice 
compared to wild type littermates (Ferguson et al., 2004). My current studies show that
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Figure 20. Muscarinic receptor expression is selectively diminished in the CHT+/- 
brain. Immunoblotting shows that M1 receptor expression is significantly downregulated 
in the CHT+/- striatum (A), while M2 receptor expression is decreased in both CHT+/- 
cortex and striatum (B). Mean (+/-SEM) values are indicated (n=4 mice per genotype) 
(*p<0.05). Data obtained through collaborative effort with Allan Levey lab. Craig 
Heilman contributed to this figure. 
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CHT+/- mice achieve normal baseline performance on multiple sensorimotor, anxiety 
and cognitive tasks, consistent with our findings of normal levels of synaptosomal, CHT-
mediated HACU (Ferguson et al., 2004). In addition, I demonstrate that physical and/or 
pharmacological challenges elicit genotype-sensitive phenotypes, consistent with 
demand-dependent cholinergic hypofunction based on diminished bulk ACh levels. 
 Cholinergic neurotransmission at the NMJ is essential for movement (Brandon et al., 
2003; Misgeld et al., 2002) and ACh modulates extrapyramidal motor function (Borison and 
Diamond, 1987; Kaneko et al., 2000). Therefore, I began by characterizing motor function in 
the CHT+/- mice, using the open field chamber paradigm. Whereas overall levels of activity 
were not different between the genotypes (Fig. 11C), we did observe an interesting pattern of 
decreased horizontal (Fig. 11A) but increased vertical movement (Fig. 11B) by the CHT+/- 
mice. This phenotype did not appear to be caused by overt musculoskeletal deficits, as 
CHT+/- mice travel equivalent distances at swimming velocities similar to CHT+/+ 
littermates in the Morris water maze (data not shown), perform comparably to CHT+/+ mice 
at slow speeds and short test intervals on the treadmill (Fig. 15), and are not impaired in the 
rotarod (Fig. 12A), wire hang, and inverted screen tests (data not shown). Normal basal 
performance by the CHT+/- mice in the elevated plus maze (Fig. 12B) and light/dark (Fig. 
12D) paradigms likely rules out anxiety as an alternative reason for the altered locomotor 
phenotype. The increased rearing, but preserved overall activity levels, may be interpreted as 
an altered cognitive response to a novel environment (Sarter and Bruno, 1997), resulting in a 
unique pattern of exploratory behavior. Additional studies are needed to discern whether 
altered patterns of autonomic activity may also contribute to this phenotype.  
 The baseline locomotor data described above not only provide controls for studies of 
stressed motor function, but also allowed me to proceed with cognitive studies that rely on 
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normal motor function. Similar to motor activity, cognitive performance in CHT+/- mice 
appeared grossly normal at baseline in multiple behavioral assays, including spontaneous Y 
maze and rewarded T maze alternation, conditioned freezing, operant conditioning, and 
prepulse inhibition (data not shown). CHT+/- mice were also unimpaired in the Morris water 
maze - a hippocampus-dependent spatial learning and memory task that is sensitive to insults 
on the cholinergic system, including pharmacological challenges with muscarinic 
antagonists, aging, and anatomical lesions of cholinergic pathways (Gage et al., 1988). 
However, Morris water maze performance is unaffected in other models of cholinergic 
dysfunction, including M1 knockouts (Miyakawa et al., 2001) and ChAT heterozygous 
(ChAT+/-) mice (Brandon et al., 2004). Interestingly, the normal water maze performance of 
ChAT+/- mice in particular has been attributed to wild type levels of cholinergic 
neurotransmission capacity, triggered in part by upregulation of CHT (Brandon et al., 2004). 
In this context, additional tests, such as those developed in the rat to monitor focused 
attention (Apparsundaram et al., 2005; Sarter and Bruno, 1997) may be useful in assessing 
CHT contributions to cognitive performance.  
Following observations of normal baseline motor and cognitive performance, I 
asked whether CHT hemizygosity would render the CHT+/- mice susceptible to 
challenges directed at cholinergic neurotransmission, specifically stresses that interfere 
with choline transport or enhance ACh turnover. If cholinergic neurons actively control 
CHT localization or activity to regulate ACh synthesis and homeostasis, then in response 
to sublethal in vivo concentrations of HC-3 there should be compensatory recruitment of 
CHTs (Rylett et al., 1993) that may no longer be sustainable in CHT+/- mice. Indeed, I 
observed lethality in CHT+/- mice at concentrations of HC-3 where all wildtype mice 
survived (Fig. 14D). These results are functionally consistent with either depleted 
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intracellular CHT reserve pools, and therefore impaired recruitment to the plasma 
membrane (“trafficking” hypothesis of CHT regulation, (Ferguson et al., 2003)), or 
altered availability of active transporters on the plasma membrane independent of 
trafficking mechanisms (“activation” hypothesis). With respect to functional 
compensation (wildtype levels of choline uptake in the CHT+/- brain, see below) and in 
vivo antagonist sensitivity in the CHT heterozygotes, I note parallels to the serotonin 
transporter (SERT) +/- mice. SERT+/- exhibit wild-type rates of serotonin transport in 
synaptosome preparations but are more sensitive than the SERT+/- mice with respect to 
their locomotor response to 3,4-methylenedioxymethamphetamine (Bengel et al., 1998). 
Having established a pharmacologically induced phenotype in the CHT+/- mice, I 
next chose motor performance as a readout of challenges directed at cholinergic 
neurotransmission, as Ie could introduce both physical and pharmacological challenges in 
multiple paradigms. In treadmill tests of physical strain on locomotion, I found that 
CHT+/- mice remained on the running belt for significantly shorter periods of time (Fig. 
15A) and were not able to reach and sustain the higher speeds attained by age, gender, 
and weight-matched CHT+/+ littermates (Fig. 15B). Our previous electrophysiological 
recordings at the NMJ documented normal baseline ACh stores and release in the CHT-/- 
mice as measured by EPSP magnitude (Ferguson et al., 2004). However, over time, the 
ACh release diminished to a point where EPSP’s as well as mEPPs were no longer 
observable in the CHT-/- preparations, while CHT+/+ NMJs maintained cholinergic 
neurotransmission. Although I did not measure neuromuscular signaling per se in these 
studies, previous studies have shown that reduction in mEPP amplitude, reflecting 
diminished neurotransmitter release, is significantly greater if the prolonged nerve 
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stimulation takes place in the presence of the specific CHT inhibitor HC-3, a 
pharmacological parallel to the genetic deficit induced in the CHT+/- mice (Jones and 
Kwanbunbumpen, 1970). Therefore, I hypothesize that CHT+/- treadmill performance 
was impaired due to inability to sustain ACh turnover at the NMJ under conditions of 
high demand. 
Central cholinergic pathways support the motor program both at brainstem and 
basal ganglia levels. A paradigm that allowed the simultaneous investigation of central 
cholinergic drive of locomotion and specific challenge to the muscarinic receptor 
component of ACh turnover, is scopolamine-driven locomotion in the open field 
paradigm (Sipos et al., 1999).  It is well established that scopolamine acts at presynaptic 
auto-inhibitory muscarinic receptors, resulting in massive ACh release, a corresponding 
increase in CHT-mediated choline uptake needed to sustain ACh turnover, and 
hyperlocomotion easily measured as distance traveled in the open field (Douglas et al., 
2001; Parikh et al., 2004). My hypothesis was that, under prolonged stimulation, ACh 
turnover would not be sustainable in the CHT+/- mice, and therefore CHT+/- mice would 
lack the scopolamine-induced hyperlocomotion evident in their CHT+/+ littermates.  
Indeed, while a low dose of scopolamine (0.1 mg/kg) failed to elicit a locomotive effect 
in either genotype, an intermediate dose (0.5 mg/kg) led to significant increases in 
distance traveled by the CHT+/+ but failed to affect the CHT+/- mice.  This finding was 
particularly interesting in the context of our previous findings with AChE-/- mice, which 
display normal basal locomotion in the open field chambers, but are hyper-sensitive to 
challenge at this same intermediate dose of scopolamine (0.5 mg/kg) (Volpicelli-Daley et 
al., 2003b). The reverse response to scopolamine can be explained if we view the   
 88
AChE-/- condition as a potential hypercholinergic state, in contrast with the potential 
hypocholinergic status of CHT+/- mice. Consistent with this idea, CHT expression is 
approximately 50% higher in the AChE-/- mice, but 50% lower in the CHT+/- mice 
(Beeri et al., 1997; Volpicelli-Daley et al., 2003b). 
The normal behavioral phenotype of CHT +/- mice in many tasks parallels the 
wild type levels of synaptosomal HACU activity we previously established (Ferguson et 
al., 2004). However, the altered sensitivity to cholinergic pharmacological (HC-3, 
scopolamine, oxotremorine) challenges suggests that other determinants of ACh signaling 
are altered in the model. Accordingly, I found CHT+/- mice to have normal ChAT and 
AChE activities (see Results, this chapter), but diminished bulk ACh (Fig. 19A) and 
increased total choline brain levels (Fig. 19B). Whereas total endogenous ACh levels are 
significantly lower in the CHT+/- brain, preliminary studies show normal basal 3H-ACh 
release as measured in an in-vitro slice-perfusion paradigm (D. Lund and M. Bazalakova, 
unpublished data), suggesting that a redistribution and altered regulation of ACh release 
and reserve pools (Neher, 1998) may compensate for reduced overall ACh levels. 
Decreased bulk ACh and increased total choline brain levels have been observed 
in several human pathologies and mouse models, including the PDAPP transgenic mouse 
model of Alzheimer’s disease (Bales et al., 2006). Elevated choline levels in the CHT+/- 
mice likely represent a compensatory attempt to enrich the choline supply pool for ACh 
synthesis. Unlike the impairments seen in AChE transgenic mice (Meshorer et al., 2005), 
I have little reason to suspect major blood-brain-barrier dysfunction leading to increased 
choline flux in the CHT+/- brain. Therefore, elevated choline levels likely represent 
either a reduction in the recycling and/or ACh-incorporation of HACU-derived choline, 
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or increased membrane phosphatidyl turnover, resulting from an attempt to increase 
choline reserves available as precursors for ACh synthesis (Lee et al., 1993). The 
decreased bulk ACh levels, but normal exogenous 3H-choline conversion and release of 
3H-ACh from slices, suggest a possible redistribution of ACh pools (Birks and 
MacIntosh, 1961), where readily-releasable pools are not different from wild type 
(possibly sustained by increased choline levels), but reserve pools are compromised. 
These observations parallel my behavioral findings of normal baseline performance, but 
challenge-induced deficits in cholinergically-mediated function.  
What mechanisms regulate CHT function and lead to compensation for depleted 
ACh reserves in the CHT+/- brain? My findings of wild-type levels of HC-3-sensitive 
HACU in whole-brain synaptosomes from CHT+/- mice indicate an unrecognized 
capacity of cholinergic terminals to compensate for significant reductions in CHT protein 
levels. Our recent identification of a large pool of CHTs residing on a subset of 
cholinergic synaptic vesicles (Ferguson et al., 2003) pointed to the presence of a 
substantial intracellular CHT reserve in wild-type animals. The functional compensation 
that we observed in [3H]choline uptake and [3H]HC-3 binding is consistent with a 
redistribution of this vesicular pool of CHTs in CHT+/- neurons. In support of this 
speculation, the coordinated up-regulation of HACU capacity and HC-3 binding site 
density in response to stimulation of ACh release is well documented (Ferguson and 
Blakely, 2004; Lowenstein and Coyle, 1986; Simon et al., 1976). 
However, in contrast to this observation, my synaptosomal biotinylation findings 
suggest an alternative model of CHT regulation, one where levels of CHT at the CHT+/- 
plasma membrane are halved in comparison to wild type, and thus wildtype levels of 
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choline uptake are achieved at least in part through activation of plasma membrane 
resident CHT molecules. Previous studies suggest that HC-3 binding may not accurately 
reflect protein density, but may instead be influenced by Ca2+-dependent, ATP-induced 
changes in affinity for the ligand (KD) (Chatterjee and Bhatnagar, 1990; Saltarelli et al., 
1990). Therefore, equal measures of [3H]HC-3 binding, but disparate levels of CHT 
plasma membrane density assessed by biotinylation, may be the result of conformational 
changes of the CHT protein already present in the plasma membrane, due to 
phosophorylation or other protein modifications. Future studies will be needed to 
determine the exact mechanism of CHT regulation that predominates in the CHT+/- 
brain. 
Functional compensation in the CHT+/- mice may in part be achieved through a 
region-specific downregulation of M1 (striatum) and M2 (striatum and cortex) receptor 
expression (Fig. 20). The downregulation of muscarinic receptor expression is consistent 
with a hyposensitivity to scopolamine challenge in the CHT+/- and is reminiscent of 
compensatory changes in muscarinic expression and function in another model of 
cholinergic dysfunction – AChE-/- mice (Volpicelli-Daley et al., 2003b). I was unable to 
reliably quantify expression of the M3, M4 and M5 receptors, which may also exhibit 
CHT genotype-dependent modulation. Regardless, the hypo-responsiveness to 
scopolamine-induced locomotion and mAChR downregulation in the CHT hemizygous 
state contrasts with enhanced novelty-induced locomotion and M2 striatal overexpression 
in AChE transgenics, where CHT density and CHT-mediated choline uptake are elevated 
at baseline (Erb et al., 2001; Svedberg et al., 2003). Together, these findings reinforce an 
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interplay of CHT with muscarinic receptors in establishing and sustaining cholinergic 
tone.  
In conclusion, I have shown that CHT+/- mice perform comparably to wild type 
littermates in motor and cognitive tasks, but can display impaired performance when 
cholinergic neurotransmission is subjected to sustained physical and pharmacological 
challenge. My findings are particularly relevant in the context of the human CHT single 
nucleotide polymorphism (SNP) recently identified by Okuda and colleagues (Okuda et 
al., 2002). The I89V substitution occurs in approximately 6% of the Ashkenazi Jewish 
population and at similar or higher frequencies in North American Caucasian populations 
(B. English and R.D. Blakely, unpublished findings) and results in a 40-50% reduction in 
choline uptake measured in a transfected cell culture system (Okuda et al., 2002). Future 
studies in the CHT+/- mice can provide insights into the possible impact of the CHT 
I89V and other hypofunctioning gene variants on human behavior and physiology and 
provide a valuable new model for testing the theories and therapies related to cholinergic 
hypofunction.  
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CHAPTER IV 
 
SYSTEMIC PHYSIOLOGICAL EFFECTS OF CHT HEMIZYGOSITY  
 
Introduction 
The cholinergic system has long been implicated as playing an important role in 
various physiological processes, including cardiovascular (De Biasi, 2002; Gomeza et al., 
1999a), circadian rhythm (O'Hara et al., 1998), and dopamine (DA) release regulation 
(Zhou et al., 2003) affecting drug addiction (Dani, 2003). Pharmacological and genetic 
studies in mouse models of cholinergic dysfunction that have contributed to our 
understanding of cholinergic modulation of the aforementioned systemic physiological 
processes are reviewed below.  
 
Cardiovascular regulation 
Acetylcholine is an important regulator of cardiac function, as it mediates the 
effects of both parasympathetic and sympathetic branches of the autonomic nervous 
system on the heart. Postganglionic sympathetic innervation to the heart originates from 
the stellate and middle and superior cervical ganglia (SCG), where synaptic transmission 
is dependent on postsynaptic nicotinic ACh receptors (nAChR). The positive 
chronotropic (increased heart rate) effects of sympathetic drive are thought to be 
mediated by various nAChR subunits, including α3β4 nAChR heteromers in the mouse 
and rat SCG (De Biasi, 2002). Consequently, α3 and β4 knockout mice display 
significant bradycardia and ventricular repolarization defects (Xu et al., 1999; Yu et al., 
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2000). α7 is another nAChR subunit, which appears to be essential for baroreflex-
mediated activation of sympathetic drive, and consequent increases in heart rate 
(Franceschini et al., 2000).  
The parasympathetic nervous system uses ACh both at ganglionic and target-
organ synapses. Cholinergic terminals from the vagus nerve synapse onto nAChR-
containing intrinsic cardiac ganglia and cause postganglionic ACh release, thus activating 
muscarinic ACh receptors (mAChR) in the myocardium. Therefore, muscarinic agonists 
cause a decrease in heart rate, atrioventricular contraction, and force of contraction in 
humans in vivo, similar to parasympathetic vagal drive (Dhein et al., 2001). Conversely, 
muscarinic antagonists increase heart rate. Interestingly, these effects appear to be dose-
dependent: high doses of muscarinic agonists can have positive chronotropic effects 
(Loffelholz and Pappano, 1985), while low doses of muscarinic antagonists can have 
cholinomimetic, or negative chronotropic effects on heart rate in healthy volunteers 
(Poller et al., 1997). The latter effect is thought to be mediated by presynaptic muscarinic 
autoreceptors, which normally inhibit ACh release (Oberhauser et al., 2001).  
The predominant mAChR in the mammalian heart is M2 (Peralta et al., 1987), 
and atria from M2 receptor knockout mice are not responsive to muscarinic stimulation, 
in contrast with carbachol-induced bradycardia in atria from wild type mice (Gomeza et 
al., 1999a). In humans, an age-dependent reduction in atrial M2 receptor density appears 
to underlie decreased responsiveness to muscarinic agents (Brodde et al., 1998). The role 
of muscarinic receptors in cardiac pathology continues to be the subject of active 
investigation. While it is known that vagal output decreases in chronic heart failure 
(Eckberg et al., 1971), the exact mechanisms of this change remain to be elucidated.  
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As HACU is believed to provide critical precursor support for ACh release, 
particularly at high rates of cholinergic signaling, I predicted that a genetic perturbation 
of CHT will limit the ability of animals to sustain cholingergic signaling. With regard to 
the heart, both the sympathetic and parasympathetic innervation of the heart utilize 
preganglionic cholinergic signals, whereas postganglionic cholinergic synapses of 
parasympathetic neurons provide the ACh that slows the heart. CHT dysfunction can thus 
diminish sympathoexcitation of the heart or diminish cholinergic suppression of 
adrenergic drive. Moreover, the balance between these two opposing forces may be 
disrupted, placing the heart at risk for sudden death or drug-induced arrhythmias. 
Evaluation of the ultimate victor in this chemical tug of war led me to analyses in CHT+/- 
animals, studies that can lead to a greater awareness of phenotypes likely to be exhibited 
by human subjects with loss of function mutations in the CHT gene (Okuda et al., 2002).  
 
Dopamine (DA) Release and Addiction 
A growing body of evidence describes the importance and mechanisms of ACh 
regulation in DA release (Zhou et al., 2003) and, consequently, drug addiction (Dani, 
2003). It appears that a balance between interrelated but opposing cholinergic and 
dopaminergic signaling directly modulates basal ganglia-mediated reward (Kaneko et al., 
2000). While nigrostriatal dopaminergic projections and DA application inhibit striatal 
cholinergic neuron activity (Trabucchi et al., 1975), recent studies also suggest that 
amphetamine pretreatment sensitizes increases in cortical ACh release from nucleus 
accumbens-cortical projections (Nelson et al., 2000). In addition, cocaine, which 
prolongs the action of DA, activates cholinergic interneurons (Berlanga et al., 2003) and 
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increases ACh release measured by microdyalisis (Mark et al., 1999) in the nucleus 
accumbens of self-administering rats. 
Reciprocal studies have shown that striatal cholinergic interneurons in turn 
regulate DA release from nigrostriatal projections through presynaptic ß2 nicotinic ACh 
receptors (nAChRs), and that depletion of ACh reduces DA release in the (Zhou et al., 
2001). Ventral tegmental area (VTA) dopaminergic neurons are activated by input from 
pedunculopontine tegmental (PPT) cholinergic projections (Bolam et al., 1991; Oakman 
et al., 1995), providing yet another example of ACh-induced DA release (Blaha et al., 
1996), albeit one mediated by M5 presynaptic receptors (Forster et al., 2002). M5 
knockout mice demonstrate reduced response to morphine (Basile et al., 2002) and 
cocaine (Thomsen et al., 2005) in conditioned place preference and self-administration 
paradigm, thus leading to the hypothesis that CHT+/- mice may display decreased 
sensitivity to cocaine or other drugs of abuse. 
However, M1 AChR deficiency in M1 knockout (-/-) mice results in increased 
DA release in the striatum, associated with hyperlocomotion and increased response to 
amphetamine (Gerber et al., 2001). Ablation of cholinergic cells in the nucleus 
accumbens, the ventral part of the striatum, also increases sensitivity to cocaine and 
morphine in the conditioned place preference paradigm (Hikida et al., 2003). While the 
exact molecular mechanisms are not clear, it is thought that these effects are mediated by 
dopaminergic hyperactivity due to ACh depletion. This leads to the converse hypothesis 
that CHT+/- mice may display enhanced sensitivity to cocaine under basal or induced 
conditions. 
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CHT+/- mice offer the valuable opportunity to expand our mechanistic 
understanding of the effects of cholinergic dysfunction on addiction. Our investigations 
in the whole animal avoid the potential limitations of nonspecific pharmacological and 
lesion approaches, and offer important insight into the specific contribution of CHT and 
the effects of its genetic manipulation on DA release and cholinergic modulation of 
reinforcement behavior. 
 
Cholinergic Modulation of Circadian Rhythms 
 Acetylcholine is a well-known modulator of mammalian circadian rhythms, and 
was, in fact, “the first neurotransmitter identified as a regulator of mammalian circadian 
rhythms“ (Buchanan and Gillette, 2005). Studies show the existence of cholinergic 
projections from the brainstem and basal forebrain to the suprachiasmatic nucleus (SCN) 
– a brain region considered essential for circadian rhythm regulation (Bina et al., 1993). 
The evidence for cholinergic involvement in circadian rhythm modulation includes 
demonstrations of light-induced ACh release in the SCN (Murakami et al., 1984), 
carbachol-induced phase shifts of circadian rhythms in vivo (Bina and Rusak, 1996; 
Colwell et al., 1993), and altered SCN neuron firing frequency in slices in response to 
both muscarinic (Liu and Gillette, 1996) and nicotinic (Miller et al., 1987; O'Hara et al., 
1998) stimuli. Based on these previous findings, I hypothesized that CHT+/- mice may 
display alterations in baseline circadian rhythms and/or light-induced phase-shifts in 
circadian activity. 
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Methods 
 
Subcutaneous electrocardiogram recordings (ECG) 
 All cardiovascular studies were performed in collaboration with the Robertson lab 
at Vanderbilt, with excellent technical expertise and assistance from Martin Appalsamy, 
and helpful discussions with Nancy Keller. Mice were anesthesized with 1.5% isoflurane. 
Three tiny skin needles were fixed on three extremities to record ECG lead II. The ECG 
signal was amplified with open filter set (GOULD, dx mode, 0-500 Hz) to prevent 
minimal distortion of QRS complex. The data was recorded using a WINDAQ data 
acquisition system (DI410, DATAQ, Acron, OH, 14 Bit, 1000Hz) and processed off-line 
using a custom written software in PV-Wave language (PV-wave, Visual Numerics Inc., 
Houston, TX).  
 
Placement of Telemetric ECG Device 
Recordings were performed following modifications of previously described 
protocols (Wu et al., 2002). Mice were anesthetized with 2-3% isoflurane (in 100% O2) 
and placed on an isothermal pad (Deltaphase; Braintree Scientific, Inc., Braintree MA) to 
maintain body temperature at 36-37 C. Hair in the ventral neck region was removed with 
a dipilatory agent (Nair, Carter-Wallace, New York NY) and the skin prepared with 
antiseptic (betadine followed by alcohol). As soon as the animal demonstrated an absence 
of withdrawal response to nociceptive stimulation of a hindpaw, a 1 cm dorsal 
midscapular incision was made for placement of the radio transmitter in a subcutaneous 
pocket formed through the incision site by blunt dissection and sutured (7-0 silk) in place.  
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Two recording electrodes extending from the transmitter body were inserted into the 
underlying muscle surface and sutured in place, one in the chest wall and the other in the 
right axillary region.  Care was taken to place the recording electrodes in such a way that 
no pressure is exerted onto the skin. Animals received an intramuscular injection of 
prophylactic cefazolin (30 mg/kg) and 1 ml of subcutaneous Lactated Ringer’s solution to 
replenish fluids. The skin was sealed with sutures (5-0 absorbable synthetic) and secured 
with Nexaband veterinary adhesive. Animals were placed in individual cages on a heated 
isothermal pad until fully recovered from anesthesia. Mice were allowed at least 7 days to 
recover before experimentation. 
 
Spectral Analysis 
Beat-to-beat values of R-R intervals (Pan and Tompkins, 1985) are interpolated, 
low pass filtered (cutoff 3 Hz), and re-sampled at 6 Hz.  Data segments of 128 seconds 
are used for spectral analysis. Linear trends were removed and power spectral density are 
estimated with the Fast Fourier Transform-based Welch algorithm using segments of 256 
data points with 50% overlapping and Hanning window. The power in the frequency 
range of low frequencies (LF=0.250-0.600 Hz) and high frequencies (HF=1.0-3.0 Hz) 
was calculated in 5 90s segments for recordings obtained between the hours or 8 am-12 
pm where the mice were not physically active. The frequency bands were adapted for 
analysis in mice considering the ranges of heart rate and breathing frequencies.  
 
 
 
 99
Vagal Stimulation 
 Protocols were adapted from previously published studies (Ma et al., 2002; 
Smith-White et al., 2003; Walker et al., 2004). Briefly, mice were instrumented for 
subcutaneous ECG recordings, and femoral artery blood pressure readings. The 
peripheral end of the right vagus nerve was isolated, placed across platinum electrodes, 
and cut. Two protocols for vagal stiumulation distal to the cut site were used: 1. 
frequency-response curve, where a stimulus of 16V, 2 ms, 30 sec duration  was 
administered at ascending frequencies (5Hz, 10Hz, 15Hz, 20Hz, 25Hz, 50Hz), separated 
by a 2 min recovery period and 2. repeated stimulation, where a stimulus of  25Hz, 16V, 
2 ms, 30 sec duration  was administered 12 consecutive times with a 10 sec inter-stimulus 
interval. 
 
Pharmacological Cardiovascular Challenges 
 Mice were instrumented for telemetry recordings and jugular intravenous (i.v.) 
catheters, allowing remote administration of drugs during awake, unrestrained behavior. 
Naïve, 1-1.5 year old, non-backcrossed, male F1 littermates were used for each drug 
administration. After recording a 15 min ECG baseline, i.v. bolus injections of one of the 
following drugs were administered: the ganglionic nAChR antagonist hexamethonium 
(30 µg/kg); the alpha receptor agonist phenylephrine (10 µg/kg); or the. muscarinic 
antagonist scopolamine (10 µg/kg followed by 25 µg/kg). 
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Dopamine Microdyalisis 
 Baseline, nicotine- and cocaine-induced dopamine (DA) release was measured 
through our collaborative effort with the John Dani lab at Baylor University, using 
published microdyalisis techniques (Pidoplichko et al., 2004). Briefly, mice were 
maintained on an isoflurane-gas mixture and the microdialysis CMA/12 
(CMA/Microdialysis) guide cannula was aimed at the nucleus accumbens shell (1.7 mm 
AP; 0.8 mm L; 6.5 mm DV, with the probe at 7.5 mm) and was secured with bone wax 
reinforced with acrylic cement and three screws into the skull. The mouse was allowed to 
recover fully for a minimum of 48 h.   
CMA/12 probes (diameter, 0.5 mm; length, 1 mm; membrane, polycarbonate; 
cutoff, 20,000 D) were prepared, and filtered degassed artificial cerebrospinal fluid 
(aCSF; from ESA) was perfused through the probe at a flow rate of 1 µL/min using a 
CMA/100 pump. Following a 2-h recovery period, three 20-min fractions were collected 
to assess the basal output of dopamine in the dialysate. Subsequently, saline and nicotine 
(1.0 mg/kg i.p.) were injected 1 hour apart, and samples were collected every 20 min for 
4 hours following the nicotine injection. At the end of the 4 hours cocaine (10mg/kg) was 
injected, and samples were collected every 20 min for 1 h. After these experiments, mice 
were killed with an overdose of anesthetics and trans-cardially perfused with PBS and 
then 10% formalin. The brain was removed and fixed in 10% formalin. The accuracy of 
probe placement was later confirmed by histological sectioning.  
Dopamine contents of microdialysates were determined using a high-performance 
liquid chromatography (HPLC) system (model 580 pump, Coulochem II electrochemical 
detector, model 5014B analytical cell; ESA, Inc.). Separation of dopamine was achieved 
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on a 150 x 3 mm column with 3 µm particle size (ESA, Inc.; MD-150). An isocratic 
mobile phase (pH 4.0) containing 75 mM NaH2PO4, 2 mM 1-octane sulphonic acid-
sodium salt, 20 mM EDTA, 100 µL/L triethylamine, and 18% methanol (from ESA) was 
used at a flow rate of 0.6 mL/min. This mobile phase and the protocols used produced 
clearly separable dopamine peaks with a retention time of 5.6 min. Chromatograms were 
analyzed with the ESA software. Freshly prepared standards ranging from 0–6 nM DA 
were used to calibrate the readings. 
  
Cocaine Self-Administration 
The self-administration protocol used in our collaboration with the Danny Winder 
lab at Vanderbilt University has been described in detail (Olsen and Winder, 2006). 
Briefly, food-restricted, handled, male mice at 7–9 weeks of age were trained to lever 
press in Med Associates (E. Fairfield, VT) operant chambers on a fixed ratio 1 (FR-1), 
followed by progressive ratio (PR) schedule of liquid reinforcement (25% Ensure). Mice 
successfully completing food training were catheterized in the right jugular vein with a 
SILASTIC catheter. After at least 3 days of recovery with food and water available ad 
libitum, the mice were subjected to a single, overnight, PR session of self-administration, 
in which pressing of the active lever resulted in delivery of saline or cocaine (0.3 mg/kg 
or 0.6 mg/kg per infusion in 0.040 ml). Within an hour after the last administration 
session, catheter patency was verified. Only animals that had patent catheters were 
included in subsequent data analyses as well as synaptosomal striatal 3H-choline uptake 
experiments. 
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Circadian Rhythms and Light Entrainment 
Male animals, 11 CHT+/+ and 13 CHT+/-, were placed in wheel-cages with food 
and water ad libitum.  These cages were placed in 12-hr light:12-hr dark cycles (LD) for 
one week with lights on from 06:00 to 18:00. The light cycle was then phase-shifted 6 
hours forward, so that lights-on occurred between 0 and 12:00.  This schedule was also 
maintained for a week.  Animals were then subjected to constant darkness for a week and 
allowed to free-run before being placed back on the original 0600 to 1800 LD cycle.  
After another week in these LD conditions, animals were removed from the coffins and 
activity data was analyzed by ClockLab software. 
 
Results and Discussion 
 
Cardiovascular Regulation is Altered in the CHT+/- Mice 
All cardiovascular data was obtained through a collaborative effort with the 
Robertson lab at Vanderbilt University. ECG recordings show that the CHT-/- neonates 
display two phenotypes: 1. Low average heart rates (Fig. 21): the newborn homozygote 
average heart rate is significantly lower than wild type (80±15 bpm, (CHT-/-), n=14 vs 
220±22 bpm, (CHT+/+), n=4); 2. Prolonged PR intervals: the PR interval was found to be 
approximately twice as long in the CHT-/- newborns 120-140 ms (vs approximately 60-
100 ms long PR interval in +/+ newborns). This may be an interesting finding, since the 
PR interval depends on AV node conduction, and the AV node receives heavy 
cholinergic innervation. While these findings may clearly be compromised by the 
hypoxia induced by increasingly labored breathing in the CHT -/- neonates, in utero
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Figure 21. Average heart rates are significantly higher in CHT+/ neonates. ECG 
recordings were obtained in unanesthetized newborns, using a lead II position Gould 
Amplifier and WinDaq Acquisition System. Mean heart rate values were 276±9 bpm in 
the CHT+/- (n=6), 220±22 bpm in the CHT+/+ (n=4), and 80±15 bpm in the CHT-/- 
(n=12) * p<0.05, two-tailed t-test (values +/- SEM). 
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recordings can be used in the future to determine any intrinsic changes in heart rate. 
Importantly, the CHT+/- newborns seem to also display a phenotype: the CHT+/- average 
heart rate (276±9 bpm, n=6) appears to be significantly higher than the wild type average 
heart rate (220±22 bpm, n=4) (Fig. 21).  
In order to avoid the complications of CHT-/- anoxia and lethality, I focused on 
characterizing basal heart rates in adult CHT+/- animals. I first used subcutaneous ECG 
electrode recordings in isofluorane-anaesthetized mice, and confirmed the finding of 
higher basal heart rates in CHT+/- adults compared to wildtype siblings (Fig. 22), which I 
had also observed in the newborns. To avoid potentially confounding effects of 
anesthesia we then instrumented mice with telemetric devices, allowing us to record heart 
rate in freely-moving, awake animals. Preliminary results appear to confirm the higher 
basal heart rate phenotype in the CHT+/-s (Fig. 23).  
Several potential mechanisms could underlie the observed phenotype, including 
diminished parasympathetic drive or sympathetic overdrive. One approach to investigate 
possible alterations in autonomic balance is provided by spectral analysis of heart rate 
variability (HRV). In mice, muscarinic blockade decreases the amplitude of low 
frequency (LF) (below 1 Hz) oscillations in heart rate, while increases in sympathetic 
tone increase the prominence of 0.4Hz LF variability. Thus, if CHT+/- mice have 
decreased parasympathetic drive, I expect to find decreased LF HRV, while sympathetic 
overdrive would lead to increased LF HRV. Preliminary analyses suggest that the 
CHT+/- mice display decreased low-to-high frequency heart rate variability ratio, 
indicative of parasympathetic withdrawal (Fig. 24). These findings are particularly 
interesting in light of a recent human genotyping study, which showed an association 
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Figure 22. Average heart rates are significantly higher in isofluorane-anaesthetized 
CHT+/- adults. Subcutaneous ECG recordings were obtained in 1.5 year old, adult, male 
CHT+/- and CHT+/+ siblings, under 1.5% isofluorane anaesthesia, using a lead II 
position Gould Amplifier and WinDaq Acquisition System. * p<0.05, two-tailed t-test 
(values +/- SEM). 
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Figure 23. Telemetry recordings confirm significantly higher average heart rates in 
awake, freely-behaving CHT+/- mice. Telemetry recordings were obtained in freely-
behaving, awake, 8-10 weeks old male mice, using implanted telemetry devices; HR = 
heart rate; WT = CHT+/+ (n=4); HET = CHT+/- (n=4). Data obtained in collaborative 
effort with David Robertson’s lab. Figure contributed by Andre Diedrich.  
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Figure 24. Spectral analysis of heart rate variability suggests parasympathetic 
withdrawal in CHT+/- mice. The power in the frequency range of low frequencies 
(LF=0.25-0.60 Hz) and high frequencies (HF=1.0-3.0 Hz) was calculated in 5 90s 
segments for telemetry recordings obtained between the hours or 8 am-12 pm when the 
mice were not physically active.  WT =  CHT+/+ (n=5); HET = CHT+/- (n=4). Laura 
Miller contributed to this figure through collaborative effort with David Robertson lab. 
 
 108
between lower LF/HF ratios and a single nucleotide polymorphism in the CHT 3’ 
untranslated region (Neumann et al., 2005). 
If CHT+/- mice indeed suffer from parasympathetic withdrawal, it is reasonable 
to hypothesize that their response to vagal stimulation may be compromised. It can also 
be postulated that CHT+/- mice may not be able to sustain repeated stimulation of the 
isolated cut vagus by an electrode, as ACh turnover and release may be compromised at 
the CHT+/- vagal terminal. In order to test these hypotheses I used a vagus stimulation 
protocol in anaesthetized adult male mice, and recorded bradycardic responses as a 
readout. CHT+/- mice displayed a frequency-response vagal stimulation curve 
indistinguishable from wild types (Fig. 25), which was not surprising in light of 
numerous behavioral and biochemical measures that are unaltered between the genotypes 
at baseline (Chapter III). However, I was surprised to find CHT+/- mice more, instead of 
less, responsive to repeated vagal stimulation (Fig. 26). While this finding did not follow 
my initial experimental predictions, it could potentially be explained in the context of 
altered sympathetic-parasympathetic balance, mediated by various mechanisms such as 
hypersensitive ganglionic nicotinic receptors or hyposensitive peripheral presynaptic 
muscarinic receptors. Pharmacological studies described below address these hypotheses. 
Alterations in both sympathetic and parasympathetic innervation could be 
mediated by changes in sensitivity of cholinergic receptors at the ganglionic or 
postganglionic level. nAChRs are found at both sympathetic and parasympathetic 
ganglia, and α7 nAChR’s have been implicated in the positive chronotropic effects of 
sympathetic activation. Target-organ muscarinic AChR’s, predominantly of the M2 
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Figure 25. Vagal stimulation decreases heart rate in a frequency-dependent manner 
in both CHT+/- and CHT+/+ mice. Subcutaneous ECG recordings were used to 
evaluate bradycardia evoked by right vagal stimulation, using a 2 ms, 16 V, 30 sec 
duration pulse, in isofluorane-anaesthetized, 1.5 year-old, male mice. The genotypes did 
not differ in their responses. 
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Figure 26. CHT+/- mice display greater bradycardia in response to repeated vagal 
stimulation. Subcutaneous ECG recordings were used to evaluate bradycardia evoked by 
right vagal stimulation, using a 25 Hz, 2 ms, 16 V, 30 sec duration pulse, in isofluorane-
anaesthetized, 1.5 year-old, male mice. The CHT+/- mice display a trend towards greater 
capacity for vagally-induced bradycardia. 
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subtype, mediate vagal innervation of the heart, resulting in bradycardia following 
parasympathetic activation. In order to investigate possible alterations in nAChR and 
mAChR function and therefore altered sensitivity to nicotinic and muscarinic agents in 
the CHT+/- mice, we instrumented CHT+/- and CHT+/+ siblings with ECG telemetry 
devices and jugular intravenous (IV) ports, allowing the IV administration of drugs in 
freely moving awake animals, and the subsequent recording of drug effects on heart rate 
in beats per minute (bpm). 
To address nAChR sensitivity in the context of CHT heterozygosity I challenged 
CHT+/- mice and CHT+/+ siblings with the nicotinic receptor antagonist hexamethonium 
(30 ug/kg iv). Hexamethonium treatment results in ganglionic blockade, and in mice, 
where sympathetic tone is predominant, typically lowers heart rate. While at this dose, 
and within a short term period (less than 30 minutes), heart rates did not change 
significantly in the CHT+/+ mice and the mice appeared unaffected, heart rates in the 
CHT+/-s decreased significantly (Fig. 27) and both subjects died. This suggests 
ganglionic nAChR hypersensitivity in the CHT+/- mice.  
To characterize mAChR function, I challenged CHT+/- and CHT+/+ siblings with 
increasing doses of the muscarinic receptor antagonist metscopolamine (0.1-1 ug/kg iv). 
Muscarinic blockade blocks vagal innervation to the heart, which in mice is thought to be 
predominantly mediated by M2, and results in tachycardia, as well as reduced heart rate 
variability. While increasing doses of metscopolamine led to increases in heart rate in 
CHT+/+ mice, they did not have a large effect on CHT+/- heart rate (Fig. 28), suggesting 
a possible mAChR hyposensitivity in the CHT+/- mice. A particularly striking effect was 
the complete abolition of heart rate variability in the CHT+/- mice. 
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Figure 27. CHT+/- mice appear to be hypersensitive to ganglionic nicotinic receptor 
blockade. 1.5 year old male mice were instrumented with jugular catheters for 
intravenous (i.v.) drug administration, and heart rate responses to pharmacological 
challenge with 30 mg/kg hexamethonium were recorded in awake, freely-behaving mice 
using implanted telemetry devices. CHT+/- appeared hypersensitive to hexamethonium 
challenge as measured by heart rate responses, and also by the lethal effect of the drug 
which left the wild type siblings unaffected. WT = CHT+/+; HET = CHT+/-. 
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Figure 28. Reduced variability in CHT+/- heart rate in response to peripheral 
muscarinic blockade. 1.5 year old male mice were instrumented with jugular catheters 
for intravenous (i.v.) drug administration, and heart rate responses to pharmacological 
challenge with 10 and 20 µg/kg metscopolamine were recorded in awake, freely-
behaving mice using implanted telemetry devices. 
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Figure 29. CHT+/- mice may be less responsive to phenylephrine-induced baroreflex 
bradycardia. 1.5 year old male mice were instrumented with jugular catheters for 
intravenous (i.v.) drug administration, and heart rate responses to pharmacological 
challenge with 10 µg/kg phenylephrine (min 46 of recording) following a baseline 
recording free of drug (min 1-3 of recording) were captured in awake, freely-behaving 
mice using implanted telemetry devices. 
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Finally, in order to evaluate the functional responsiveness of the CHT+/- 
cardiovascular system, I used a phenylephrine challenge to the baroreflex response. 
Phenylephrine administration results in increased blood pressure and compensatory 
vagally-mediated bradycardia. I hypothesized that CHT+/- mice may be compromised in 
their ability to sustain cholinergic signaling underlying a prolonged vagal response, and 
thus may not be able to mount or maintain a bradycardic baroreflex response to 
phenylephrine. Indeed, while CHT+/+ animals display reduced heart rates following 
phenylephrine administration, CHT+/- mice did not seem to respond to the drug 
challenge (Fig. 29). 
 
Dopamine Release and Cocaine Self-Administration 
 Preliminary data obtained through collaborative efforts show reduced basal, as 
well as nicotine- and cocaine- evoked dopamine release in the nucleus accumbens (NAc) 
of CHT+/- mice (Fig. 31). These results not only support reduced dose-dependent cocaine 
self-administration (Fig. 32) by the CHT+/- mice (24.0±10.8 cocaine infusions at the 0.3 
mg/kg/infusion cocaine dose, compared to 47.0±8.5 infusions by CHT+/+ littermates), 
but suggest a possible mechanism underlying the phenotype – dysregulated nicotinic 
receptors. One possible scenario involves hypofunctioning postsynaptic nicotinic 
receptors NAc on dopaminergic terminals, resulting in reduced DA release. Another 
potential mechanism may involve hyposensitive presynaptic nicotinic receptors, resulting 
in reduced ACh release and, consequently, lower DA release. The latter hypothesis is 
especially important in light of previous demonstrations of increased ACh release in the 
rat NAc and my findings of increased choline uptake in the striatum of cocaine self- 
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Figure 30. Cocaine self-administration increases HACU in striatum of C57Bl6 mice. 
HC-3-sensitive 3H choline transport assays were performed in striatal synaptosomes of 
C57Bl6 wild type mice following saline or cocaine self-administration; one-sample t test 
against a theoretical value (100% for saline controls). Data obtained through 
collaborative effort with Chris Olsen, Danny Winder lab. 
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Figure 31. Baseline, nicotine- and cocaine-induced dopamine release is lower in the 
CHT+/- nucleus accumbens. Microdialysis was used to assess dopamine release in the 
nucleus accumbens of CHT+/+ (n=30) and CHT+/- (n=33) littermates. Following a 
baseline dialysate collection, saline and nicotine (1.0 mg/kg i.p.) were injected 1 hour 
apart. Samples were collected every 20 min for 4 hours following the nicotine injection. 
At the end of the 4 hours cocaine (10mg/kg) was injected, and samples were collected 
every 20 min for 1 h. The graph values represent averages of 3 20 min fractions 
immediately following injections (means ± sem); * P < 0.05, t test. Data obtained through 
collaborative effort with John Dani lab. This figure was contributed by Yu Dong. 
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Figure 32. CHT+/- mice appear hyposensitive to low doses of cocaine in self-
administration paradigm. Seven to 9 week old male mice were instrumented with 
jugular catheters to allow intravenous self-administration of cocaine. Whereas genotypes 
did not differ in the saline or 0.6 mg/kg cocaine conditions, CHT+/- mice self-
administered significantly fewer cocaine infusions (24.0±10.8) compared to CHT+/+ 
littermates (47.0±8.5) at a low, 0.3 mg/kg dose of cocaine. Saline, CHT+/+ (n=2), 
CHT+/- (n=1); 0.3 mg/kg cocaine CHT+/+ (n=2), CHT+/- (n=4); 0.6 mg/kg cocaine, 
CHT+/+ (n=2), CHT+/- (n=3). Data obtained through collaborative effort with Danny 
Winder lab. This figure was contributed by Chris Olsen. 
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administering wild type mice (Fig. 30). Future studies will pursue these and additional 
hypothesis to reveal the mechanisms underlying altered DA release and addictive 
behaviors in conditions of CHT hemizygosity. 
 
Circadian Rhythms 
In wheel-running studies, CHT+/- mice show a pattern of reduced running-wheel 
activity upon initial introduction to a novel environment, with activity gradually 
increasing to wild type levels as the animals habituate to the surroundings (Bazalakova et 
al, preliminary findings, data not shown). These data are interesting in the context of our 
observations of altered patterns of baseline locomotor activity in the open field paradigm 
(increased vertical rearings, but decreased horizontal counts) (Chapter III), and suggest 
that novelty-induced exploration may be subtly different in the CHT+/- mice. In addition, 
circadian rhythm generation is not altered, and CHT+/- mice display wildtype periodicity 
in 12 hour light-dark, as well as continual darkness, conditions (data not shown). 
However, a striking difference becomes apparent between genotypes in studies of light-
induced phase shifts (Fig. 33A). While only 15% of CHT+/+ mice upregulate their 
locomotor activity in the first dark period following a 6 hour light phase shift, 85% of 
CHT+/- mice respond to the phase shift almost immediately. CHT+/- activity levels are 
indistinguishable from baseline within 2 days post-phase-shift, while CHT+/+ mice 
require an additional day to recover baseline activity (Fig. 33B). Possible mechanisms 
underlying this interesting phenotype, including altered cholinergically-modulated retinal 
function and clock gene regulation, as well as muscarinic and nicotinic receptor 
expression and function in the SCN, will be investigated in future experiments.
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Figure 33. CHT+/- mice are more responsive to phase entrainment. Activity levels 
were analyzed in 6 hour increments during dark periods immediately preceding (before 
phase-shift) and on subsequent days (Day 1, 2, 3) following a 6 hour phase-shift in light-
dark exposure of adult male mice in a circadian rhythm paradigm (B). 82% of CHT+/- 
mice, but only 15% of CHT+/+ mice adapted to the light phase shift within the first dark 
period following the phase-shift (A); * p<0.05, two-tailed t-test (values +/- SEM). Data 
obtained through collaborative effort with Hidenobu Ohta and Chris Ciareglio from Doug 
McMahon lab.  
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In summary, preliminary studies using small numbers of mice suggest that CHT 
hemizygosity results in alterations in cardiovascular, dopamine release, drug addiction, 
and circadian phase shift behaviors. In cardiovascular studies, CHT+/- mice appear to be 
tachycardic, display reduced LF/HF heart rate variability ratios suggestive of 
parasympathetic withdrawal, have enhanced responsiveness to repeated vagal 
stimulation, possibly mediated by hyper-responsive ganglionic nicotinic receptors, and 
decreased heart rate variability in response to peripheral muscarinic blockade. In 
preliminary studies of dopaminergic signaling and related behaviors, baseline, as well as 
nicotine- and cocaine-induced, dopamine release is significantly reduced in the CHT+/- 
basal forebrain, providing a mechanistic explanation for reduced cocaine self-
administration by the CHT+/- mice. Circadian rhythm studies reveal a striking 
responsiveness to light-induced phase shifting by the CHT+/- mice. Future studies will be 
needed to extend these intriguing data and elucidate mechanisms underlying the observed 
phenotypes.  
 122
CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
CHT Is Required for Survival: CHT Homozygosity (CHT-/-) is Lethal 
The generation of CHT knockout mice via homologous recombination allowed 
the direct study of CHT’s physiological impact in vivo (Ferguson et al., 2004). 
Homozygous (CHT-/-) mice are born at expected Mendelian ratios, and display normal 
gross anatomy. However, CHT-/- pups appear apneic and hypoxic, are largely immobile, 
and die within an hour after birth. Electrophysiological recordings at the sternomastoid 
NMJ show that the CHT-/- animals are born with wild type stores of ACh, but are unable 
to sustain ACh synthesis and release under high demand for ACh turnover at the NMJ 
synapse, leading to motor and respiratory paralysis (Ferguson et al., 2004). Detailed 
immunofluorescence studies of the CHT-/- NMJ reveal a more subtle phenotype of 
immature NMJ formation, similar to the phenotype observed in another knockout mouse, 
ChAT-/-, which is incapable of ACh synthesis and is also not viable (Brandon et al., 
2003; Misgeld et al., 2002). Although CHT-/- homozygosity is lethal, embryonic 
neuronal cultures can be used in future studies to investigate the effects of complete lack 
of CHT on other determinants of cholinergic signaling, including muscarinic and 
nicotinic receptors, VAChT and other synaptic proteins, and  ChAT and AChE enzyme 
expression and activity. 
In addition, efforts are currently underway to rescue the CHT-/- mice. These 
include the creation of transgenic (CHT-Tg) mice over-expressing CHT under the Hb-9 
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motor-specific promoter, and the subsequent crossing of CHT-Tg and CHT+/- mice in 
order to obtain mice with CHT expression restricted to motor neurons. These mice should 
survive due to restored ACh transmission at the NMJ, yet will allow studies of central 
and peripheral function in the absence of CHT in any but motor neurons. An alternative 
approach, also being developed in the lab, is the creation of CHT floxed mice which, 
when crossed to mice expressing Cre recombinase under a forebrain- or autonomic-
specific promoter, will allow the controlled, region-specific ablation of CHT.  
Studies in either line of rescue mice will provide invaluable information about the 
effect of complete loss of CHT in select neuronal populations on ACh turnover and 
cholinergically-mediated behaviors supported by individual brain regions. Additionally, 
CHT-Tg mice will allow, for the first time, an investigation of the consequences of CHT 
over-expression.   
 
CHT Heterozygous (CHT+/-) Mice as Models of Cholinergic Dysfunction 
Changes in CHT function and expression have been documented in various 
mouse models of cholinergic dysfunction, suggesting an active role for CHT regulation in 
response to insults on ACh neurotransmission (Bazalakova and Blakely, 2006). These 
observations led to the hypothesis that reduced CHT reserves may result in impairment of 
cholinergically-mediated behaviors under conditions of physical or pharmacological 
challenge to cholinergic circuits. In support of this idea, CHT+/- mice display an increase 
in sensitivity to the lethal effects of HC-3 compared to wild type littermates (Ferguson et 
al., 2004). 
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Functional Compensation and Normal Basal Behaviors in CHT+/- Mice  
Under normal conditions, CHT+/- mice survive to adulthood, are capable of 
sustaining basal sensory-motor behaviors, reproduce, and generally appear 
indistinguishable from their wild type siblings. These observations are supported by the 
functional compensation evident in biochemical studies: synaptosomal uptake assays 
show that choline transport in CHT+/- mice is comparable to uptake in CHT+/+ controls 
(Ferguson et al., 2004). In addition, ChAT and AChE activities are unchanged in the 
CHT+/- brain (Ferguson et al., 2004); (Bazalakova et al, 2007; Chapter III). In our initial 
behavioral investigation of this model, CHT+/- performance is indistinguishable from 
wild type in a wide variety of behavioral tasks, including sensory-motor (Irwin screen, 
pre-pulse inhibition), motor coordination (rotarod and wire hang), overall locomotor 
activity (open fields), anxiety (elevated plus maze, light-dark paradigm) and spatial 
learning and memory tests (Morris water maze, spontaneous Y maze alternation, 
rewarded T-maze alternation) (Bazalakova et al., 2007). 
In light of the alterations in brain ACh and choline levels (possibly in the form of 
compromised ACh reserve pools and/or precursor choline availability) and challenge-
induced phenotypes discussed below, it will be of great interest to repeat the above 
behavioral studies under physical or pharmacological challenges directed at cholinergic 
transmission. For example, I would predict dose-dependent impairments in CHT+/- 
performance in the Morris water maze or T maze in response to scopolamine challenge.  
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Physical and Pharmacological Challenges Reveal Motor Phenotypes in CHT+/- Mice 
 As opposed to relatively normal spontaneous behavior, focused challenges reveal 
that CHT+/- mice are vulnerable to sustained demands on cholinergically-supported 
behaviors. For example, CHT+/- mice are capable of sustaining running on a treadmill at 
low speeds or for short periods of time, but they are unable to reach treadmill speeds as 
high as those attained by CHT+/+ littermates. At a constant high speed, CHT+/- mice 
fatigue sooner than CHT+/+ controls. Pharmacological challenges also reveal motor 
phenotypes in CHT+/- mice. Specifically, CHT+/- mice are hyposensitive to muscarinic 
antagonist (scopolamine)-induced increases in locomotion, and display a trend towards 
hypersensitivity to muscarinic agonist (oxotremorine)-induced tremor (Bazalakova et al., 
2007).  
 Electrophysiological studies of ACh release at the adult CHT+/- NMJ, as well as 
detailed morphological examination of muscle anatomy, would be of great value in 
addressing our hypotheses and ascertaining the exact mechanism underlying motor 
phenotypes in the CHT+/- mice. Future studies can also examine additional physiological 
effects of the muscarinic drugs already used, such as salivation in response to 
oxotremorine, or hypothermia in response to scopolamine, in order to specify the 
particular cholinergic pathways most affected by hemizygosity in the CHT+/- mice.  
 
ACh Homeostasis and mAChR Expression Are Altered in CHT+/- Mice 
 The altered sensitivity of CHT+/- mice to muscarinic agents may be explained by 
region-specific changes in mAChR expression. Indeed, immunoblot studies using 
mAChR specific antibodies demonstrate decreased M1 (striatum) and M2 (cortex and 
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striatum) protein expression (Bazalakova et al, 2007). These findings are particularly 
interesting in light of the alterations of muscarinic receptor expression found in 
conjunction with changes in CHT protein levels in other mouse models of cholinergic 
dysfunction, including AChE-/- and AChE-Tg mice (Erb et al., 2001; Svedberg et al., 
2003; Volpicelli-Daley et al., 2003b). 
 It will be of interest to quantify M3, M4, and M5 expression in the CHT+/- brain, 
as well as evaluate CHT+/- mice performance in behaviors that are known to be altered in 
various mAChR knockouts. For example, cocaine self-administration is diminished in 
M5 knockouts, while amphetamine-stimulated locomotion is enhanced in M1 knockout 
mice (Gerber et al., 2001; Thomsen et al., 2005). Future studies will address these and 
similar questions, leading to a better understanding of the interplay between CHT and 
mAChRs in the maintenance of ACh turnover, physiological cholinergic signaling, and 
psychostimulant action. In particular, functional studies of mAChR, such as carbachol-
induced GTPγS stimulation in brain slices, can reveal valuable new information about 
mAChR function in the CHT+/- brain.  
Our findings of reduced ACh and elevated choline levels in the CHT+/- brain 
have been observed in other mouse models of cholinergic dysfunction, including the 
PDAPP transgenic mouse model of Alzheimer’s disease. PDAPP mice overexpress the 
human Ab peptide and display behavioral abnormalities, amyloid deposition and plaque 
formation in the absence of overt cell loss. In vivo microdialysis demonstrates lower 
basal ACh tissue levels but higher extracellular choline levels in the PDAPP transgenic 
hippocampus (Bales et al., 2006). Surprisingly, whereas ACh efflux is lower in the 
hippocampi of scopolamine-treated PDAPP mice compared to scopolamine-treated wild 
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types, ACh efflux is significantly higher compared to wild type in PDAPP mice exposed 
to a novel environment, suggesting that a redistribution and altered regulation of ACh 
release and reserve pools may serve to compensate for reduced overall ACh levels. The 
authors interpret the elevated extracellular choline levels as another attempt to 
compensate for decreased ACh levels. Interestingly, HACU Vmax is approximately 50% 
higher in PDAPP synaptosomes, suggesting that the efficiency of transport and/or 
targeting of HACU-derived choline is disrupted in the PDAPP brain, possibly by CHT 
mislocalization on the plasma membrane.  
The complementary findings in CHT+/- and PDAPP Tg mice point to the 
fascinating possibility of creating a new mouse model of cholinergic dysfunction by 
crossing the two lines of animals. Behavioral, biochemical and pharmacological studies 
in PDAPP Tg/CHT+/- mice involving the phenotypes and various biochemical 
determinants of cholinergic signaling described in this work would complement and 
extend the data obtained in the individual mouse lines. Initial characterizations of 
variables such as β-amyloid load and rate of plaque formation and/or cell death would 
inform the relevance of the proposed hybrid line as a potential new model of 
cholinergically-related disease, specifically Alzheimer’s disease. 
In summary, CHT plays an important role in the maintenance of ACh turnover 
and cholinergic neurotransmission. Studies in various mouse models of cholinergic 
dysfunction demonstrate that CHT actively participates in compensatory pathways aimed 
at maintaining cholinergic signaling. Initial basic findings suggest that relocalization of 
vesicular pools to the plasma membrane surface constitutes a likely partial mechanism of 
CHT regulation. Our synaptosomal biotinylation results (Chapter III) and studies utilizing 
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genetically modified mouse models may reveal interesting alternatives. For example, if 
synaptosomal biotinylation or subcellular fractionation techniques demonstrate CHT 
protein presence on the plasma membrane of α3-/- brain terminals that lack HC-3 
sensitive choline uptake, a mechanism of regulation other than vesicular translocation 
will be indicated. It is also important to address the possible contribution of nAChRs to 
dysfunction and CHT regulation in the CHT+/- mice. This can be accomplished both 
through basic characterization of nAChR expression and function in the CHT+/- brain, 
and also through characterization of the effects of nicotinic agonist and antagonist 
challenges on select behaviors, such as nicotine-induced locomotion in the open field 
paradigm.  
Preliminary studies point to cardiovascular, dopamine release, drug addiction, and 
circadian phase shift phenotypes in the CHT+/- mice. In cardiovascular studies, CHT+/- 
mice appear to be tachycardic, display reduced LF/HF heart rate variability ratios 
suggestive of parasympathetic withdrawal, have enhanced responsiveness to repeated 
vagal stimulation, possibly mediated by hyper-responsive ganglionic nicotinic receptors, 
and decreased heart rate variability in response to peripheral muscarinic blockade. 
Increased sample sizes and additional experiments, such as assessment of heart rate and 
blood pressure modulation in response to physical (treadmill) or emotional (shock-
induced anxiety) challenge, will provide a clearer understanding of the role of CHT in 
cardiovascular regulation. 
In preliminary characterization of dopaminergic signaling and related behaviors, 
baseline, as well as nicotine- and cocaine-induced, dopamine release is significantly 
reduced in the CHT+/- basal forebrain, suggesting one possible mechanistic explanation 
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for reduced cocaine self-administration by the CHT+/- mice. In light of our muscarinic 
findings and studies in M5 knockout mice, it would be valuable to characterize 
muscarinic modulation of DA release and addiction behaviors in the CHT+/- mice and 
M5 expression in the CHT+/- VTA. In addition, it will be interesting to evaluate CHT+/- 
responses to other drugs of abuse, such as amphetamine, which would help distinguish 
the neuroanatomical substrates involved in the observed phenotypes. CHT+/- 
performance in paradigms such as psychostimulant-evoked hyperlocomotion in the open 
field, or conditioned place preference (CPP) will facilitate the integration of new findings 
within pre-existing research and established models of drug abuse.  
Circadian rhythm studies reveal a striking responsiveness to light-induced phase 
shifting by the CHT+/- mice. Future studies will be needed to extend these intriguing data 
and elucidate mechanisms underlying the observed phenotypes. In the context of previous 
studies of muscarinic and nicotinic modulation of circadian rhythms in wild type mice, 
nicotinic and muscarinic pharmacological challenges and analysis of consequent 
circadian rhythmicity as well as phase shift reponses by CHT+/- mice would be 
particularly interesting. In addition, characterization of cholinergically-modulated retinal 
function, as well as clock gene regulation, in the CHT+/- mice will be of importance to 
understand the neuroanatomical and molecular underpinnings of the phenotypes we have 
observed.  
In summary, the behavioral, biochemical, and pharmacological experiments 
proposed above will provide further insight into the molecular mechanisms of CHT 
function and regulation, with the eventual goal of manipulating CHT function in 
disorders of cholinergic origin.  
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